

Supporting Information
for DOI: 10.1055/s-0033-1339892
© Georg Thieme Verlag KG Stuttgart · New York 2013

A Palladium Catalyzed Domino Reaction as Key Step for the Synthesis of Functionalized Aromatic Amino Acids

Supporting Information

Tina Stark,^a Marcel Suhartono,^{a,b} Michael W. Göbel,^{*a} Mark Lautens^{*b}

^a *Institute of Organic Chemistry and Chemical Biology, Goethe University, Max-von-Laue-Straße 7, 60438 Frankfurt am Main, Germany*

^b *Davenport Research Laboratories, Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada*

m.goebel@chemie.uni-frankfurt.de; mlautens@chem.utoronto.ca

General information	2
Experimental section	2
NMR spectra	24
ee Determination and HPLC chromatograms	66
References	68

General Information:

NMR: Bruker DPX 250 (^1H : 250 MHz; ^{13}C : 63 MHz), Bruker AM 300 (^{13}C : 75 MHz; ^{19}F : 282 MHz) or Bruker Avance 400 (^1H : 400 MHz); ^1H chemical shifts (δ) are given in ppm relative to CDCl_3 (7.26 ppm) as internal standard; multiplicities are indicated as s for singlet, d-doublet, dd-doublet of doublets, t-triplet, q-quartet, m-multiplet, br s-broad singlet, * denotes rotamer signals; if necessary, ^1H , ^1H -COSY spectra were used for proton assignment; ^{13}C chemical shifts (δ) are reported with proton decoupling in ppm relative to CDCl_3 (77.0 ppm) as internal standard; ^{19}F chemical shifts (δ) are reported with decoupling in ppm. FT-IR: Perkin-Elmer 1600 series or Perkin-Elmer Spectrum Two; peaks are reported in cm^{-1} ; intensities are classified as strong (s), medium (m) or weak (w). Melting points (uncorrected): Kofler hot-plate microscope. Optical rotation: Perkin-Elmer polarimeter 241 with thermostats Haake G and Haake D8; values are given as follows $[\alpha]_{\text{D}}^{25}$ ($c = \text{g}/100 \text{ mL}$, solvent). Elementary analysis: Elementar vario micro cube; values are given in %. Mass spectrometry: Fisons VG Platform II (ESI); values are given as follows m/z ratio (intensity in %). High-resolution mass spectrometry (HRMS): MALDI Orbitrap XL (Thermo Fisher Scientific); values are given as m/z ratios. Analytical thin layer chromatography (TLC): alumina plates precoated with silica gel 60 F_{254} indicator (EMD); spots were visualized by UV light (254 nm). Flash column chromatography: Silica gel 60 (0.04 – 0.063 mm; Macherey-Nagel). Enantiomeric excesses were determined by HPLC analysis using analytical chiral columns from Daicel Chemical Industries Ltd (Chiralpak IA). Triphenylphosphine was recrystallized from EtOH. All other reagents were obtained from commercial suppliers and were used without further purification. 2,4,6-Triisopropylbenzenesulfonyl azide (tris-azide) was synthesized according to literature.^[1]

Experimental section:

1-Iodo-2-phenylbenzene (1e)^[2]

2-Aminobiphenyl (2.00 g; 11.8 mmol) was suspended in H_2O (12 mL) at 0 °C and HCl (12 M; 2.4 mL) was added. After slow addition of a solution of NaNO_2 (978 mg; 14.2 mmol) in H_2O (3 mL) the reaction mixture was stirred for 45 min at 0 °C. A solution of ice cooled KI (3.90 g; 23.5 mmol) in H_2O (3 mL) was added and the reaction mixture was allowed to warm to room temperature overnight.

The reaction mixture was extracted with Et_2O (4x) and the organic layers were washed with a HCl solution (3 M), saturated NaHCO_3 , saturated $\text{Na}_2\text{S}_2\text{O}_5$, and brine. After drying over MgSO_4 and concentration in vacuo the crude product was purified by column chromatography (pure *n*-hexane). A colourless oil (3.07 g; 93%) was obtained.

^1H NMR (250 MHz, CDCl_3): 7.96 (dd, $J = 0.8 \text{ Hz}$, 8 Hz, 1H, aryl-H), 7.44 – 7.29 (m, 7H, aryl-H), 7.04 (m, 1H, aryl-H). ^{13}C NMR (63 MHz, CDCl_3): 146.7, 144.2, 139.5, 130.1, 129.3, 128.7, 128.1, 127.9, 127.6, 98.6. IR (neat): 3056 (m), 1578 (w), 1525 (m), 1460 (s), 1426 (m), 1351 (w), 1294 (w), 1251 (w), 1159 (w), 1114 (w), 1072 (m), 1017 (s), 1004 (s), 915 (w),

858 (w), 746 (s), 699 (s), 648 (s). R_f (*n*-hexane/EtOAc, 25:1) = 0.75. **Elementary analysis:** calcd for C₁₂H₉I (280.10): C 51.46, H 3.24; found C 51.60, H 3.36.

General procedure for the conversion of aryl bromides to aryl iodides (1f, 1h, 1i); GP1:

Aryl bromide (10 mmol) was dissolved in dry THF (30 mL) and cooled to -78 °C under an argon atmosphere. *n*-Butyllithium (1.6 M in *n*-hexane; 7.5 mL; 12 mmol) was added dropwise. After 15 minutes a solution of I₂ (3.81 g; 15 mmol) in dry THF (10 mL) was added and the reaction mixture was allowed to warm to room temperature overnight.

For workup the reaction mixture was concentrated in vacuo. H₂O was added to the residue and it was extracted with DCM (3x). The combined organic phases were washed with saturated Na₂S₂O₅ solution and H₂O. After drying over MgSO₄ and concentration under reduced pressure, the crude product was purified by column chromatography.

1-Iodonaphthalene (1f)

Eluent for column chromatography: *n*-hexane/EtOAc, 50:1.

Yield: 2.16 g (85%); colourless oil.

¹H NMR (250 MHz, CDCl₃): 8.11 – 8.08 (m, 2H, aryl-H), 7.86 – 7.76 (m, 2H, aryl-H), 7.62 – 7.49 (m, 2H, aryl-H), 7.19 (t, *J* = 8 Hz, 1H, aryl-H). **¹³C NMR** (63 MHz, CDCl₃): 137.4, 134.4, 134.1, 132.1, 129.0, 128.5, 127.7, 126.8, 126.7, 99.5. **IR** (neat): 3052 (w), 2375 (w), 1555 (m), 1499 (s), 1374 (m), 1251 (m), 1200 (m), 1130 (w), 1022 (w), 944 (s), 788 (s), 763 (s). R_f (*n*-hexane/EtOAc, 25:1) = 0.75. **Elementary analysis:** calcd for C₁₀H₇I (254.07): C 47.27, H 2.78; found C 47.55, H 2.90.

9-Iodophenanthrene (1h)

Eluent for column chromatography: *n*-hexane/EtOAc, 50:1.

Yield: 2.59 g (85%); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 8.68 – 8.62 (m, 2H, aryl-H), 8.45 (s, 1H, aryl-H), 8.23 (m, 1H, aryl-H), 7.79 – 7.56 (m, 5H, aryl-H). **¹³C NMR** (63 MHz, CDCl₃): 138.6, 133.3, 133.0, 132.1, 130.7, 130.4, 127.8, 127.6, 127.5, 127.3, 127.1, 122.81, 122.75, 98.7. **IR** (KBr): 1488 (w), 1445 (w), 1366 (w), 1186 (w), 952 (w), 901 (w), 879 (m), 845 (m), 744 (s), 719 (s), 616 (w). **mp**: 89 – 91 °C (lit: 91 – 92 °C [3]). R_f (*n*-hexane/EtOAc, 25:1) = 0.70. **HRMS**: calcd for C₁₄H₉I [M]⁺ 303.9743; found 303.9744.

1-Iodopyrene (1i)

Eluent for column chromatography: *n*-hexane/EtOAc, 50:1.

Yield: 2.85 g (87%); light yellow solid after recrystallization from MeCN.

¹H NMR (250 MHz, CDCl₃): 8.50 (m, 1H, aryl-H), 8.32 – 8.00 (m, 7H, aryl-H), 7.88 (m, 1H, aryl-H). **¹³C NMR** (63 MHz, CDCl₃): 136.8, 132.6, 131.4, 131.07, 131.05, 131.0, 129.4, 128.0, 127.1, 126.5, 126.0, 125.8, 125.6, 125.5, 124.0, 96.2. **IR** (KBr): 3029 (w), 1584 (m), 1480 (w), 1451 (w), 1425 (m), 1310 (w), 1240 (w), 1200 (w), 1176 (w), 1077 (w), 1006 (m), 963 (m), 835 (s), 812 (m), 750 (m), 705 (s), 671 (m). **mp**: 85 – 87 °C (lit: 85 – 87 °C ^[4]). **R_f** (*n*-hexane/EtOAc, 25:1) = 0.65. **HRMS**: calcd for C₁₆H₉I [M]⁺ 327.9743: found 327.9741.

Anthracen-1-yl trifluoromethanesulfonate (1g)

1-Anthracenol (390 mg; 2.0 mmol) was dissolved in dry DCM (10 mL). After addition of pyridine (322 µL; 4.0 mmol) the brown solution was cooled to 0 °C and a solution of triflic anhydride (404 µL; 2.4 mmol) in dry DCM (4 mL) was added dropwise. The reaction mixture was stirred at room temperature for 1 h. Then, the reaction was quenched by addition of diluted HCl. After washing once with saturated NaHCO₃ solution and brine the organic phase was dried over MgSO₄ and purified by column chromatography (cyclohexane/EtOAc, 50:1). The product was directly used for the next step.

Yield: 587 mg (90%); yellow oil.

¹H NMR (250 MHz, CDCl₃): 8.65 (m, 1H, aryl-H), 8.48 (m, 1H, aryl-H), 8.13 – 7.98 (m, 3H, aryl-H), 7.63 – 7.52 (m, 2H, aryl-H), 7.50 – 7.38 (m, 2H, aryl-H). **¹³C NMR** (63 MHz, CDCl₃): 145.9, 132.5, 132.4, 132.3, 128.9, 128.7, 128.0, 127.0, 126.7, 124.7, 123.7, 122.1, 121.8, 121.4, 120.0, 116.8. **¹⁹F NMR** (282 MHz, CDCl₃): - 73.3.

3-Iodo-1-[(4-methylbenzene)sulfonyl]-1*H*-indole (1j) ^[5]

Indole (4.0 g; 34.1 mmol) and KOH (4.78 g; 85.3 mmol) were dissolved in DMF (60 mL). After dropwise addition of a solution of I₂ (8.73 g; 34.4 mmol) in DMF (60 mL) the brown solution was stirred at room temperature for 30 min. KOH (4.78 g; 85.3 mmol) and tosylchloride (13.65 g; 71.6 mmol) were added and the stirring was continued overnight.

H₂O was added to the reaction mixture and it was extracted with Et₂O (3x). The combined organic layers were washed with H₂O and brine before drying over MgSO₄. After concentration to dryness the crude product was crystallized from *n*-hexane. A light yellow solid (8.07 g; 60%) was obtained.

¹H NMR (250 MHz, CDCl₃): 7.96 (m, 1H, aryl-H), 7.78 (d, *J* = 8.5 Hz, 2H, aryl-H), 7.70 (s, 1H, aryl-H), 7.40 – 7.30 (m, 3H, aryl-H), 7.26 – 7.22 (m, 2H, aryl-H), 2.35 (s, 3H, CH₃). **¹³C NMR** (63 MHz, CDCl₃): 145.3, 135.0, 134.4, 132.4, 130.0, 129.8, 126.9, 125.6, 123.9, 122.0, 113.4, 66.8, 21.6. **IR** (KBr): 3119 (m), 1592 (m), 1438 (m), 1370 (s), 1267 (m), 1171 (s), 1125 (s), 1086 (s), 1017 (s), 920 (m), 803 (m), 753 (m), 688 (s), 653 (s), 574 (s), 532 (s). **mp**: 131 – 133 °C (lit: 131- 133 °C ^[5]). **R_f** (*n*-hexane/EtOAc, 25:1) = 0.30. **Elementary analysis**: calcd for C₁₅H₁₂INO₂S (397.23): C 45.35, H 3.04, N 3.53, S 8.07; found: C 45.32, H 3.09, N 3.44, S 7.80.

General procedure for the Catellani reaction (2a-j); GP2:

Pd(OAc)₂ (45 mg; 0.2 mmol) and triphenylphosphine (115 mg; 0.44 mmol) were filled into an oven dried sealable tube and dissolved in dry MeCN (12 mL) under argon atmosphere. After 5 min Cs₂CO₃ (3.26 g; 10 mmol), the aryl iodide (2 mmol), 1,3-dibromopropane (2.04 mL; 20 mmol; for iodobenzene (**1a**): 2.24 mL; 22 mmol) and methylacrylate (906 µL; 10 mmol) were added. The reaction mixture was purged with argon for 5 min. After addition of norbornene (942 mg; 10 mmol) the tube was sealed and heated at 90 °C for 18 h.

For workup the cooled reaction mixture was filtered over Celite[®], washed with DCM, concentrated in vacuo and purified by column chromatography.

Methyl (2E)-3-[2,6-bis(3-bromopropyl)phenyl]prop-2-enoate (2a)

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 544 mg (67%); yellow oil.

¹H NMR (250 MHz, CDCl₃): 7.87 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 7.21 (m, 1H, aryl-H), 7.12 (m, 2H, aryl-H), 6.03 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.83 (s, 3H, COOCH₃), 3.38 (t, *J* = 6.5 Hz, 4H, CH₂-Br), 2.79 (t, *J* = 7.3 Hz, 4H, CH₂-CH₂-CH₂-Br), 2.07 (m, 4H, CH₂-CH₂-Br). **¹³C NMR** (63 MHz, CDCl₃): 166.5, 143.2, 139.0, 134.2, 128.4, 127.7, 124.8, 51.8, 33.6, 33.0, 32.0. **IR** (neat): 2949 (m), 1722 (s), 1641 (m), 1576 (w), 1456 (m), 1434 (m), 1309 (m), 1272 (m), 1195 (m), 1169 (s), 1038 (w), 984 (m), 866 (w), 793 (w), 764 (m). **R_f** (*n*-hexane/EtOAc, 3:1) = 0.70. **HRMS**: calcd for C₁₆H₂₁Br₂O₂ [M+H]⁺ 402.9903; found 402.9900.

Methyl (2E)-3-[2-(3-bromopropyl)-6-methylphenyl]prop-2-enoate (2b)

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 567 mg (95%); orange oil.

¹H NMR (250 MHz, CDCl₃): 7.86 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 7.21 – 7.08 (m, 3H, aryl-H), 6.06 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 3.83 (s, 3H, COOCH₃), 3.39 (t, *J* = 6.5 Hz, 2H, CH₂-Br), 2.82 (t, *J* = 7.5 Hz, 2H, CH₂-CH₂-CH₂-Br), 2.33 (s, 3H, CH₃), 2.08 (m, 2H, CH₂-CH₂-Br). **¹³C NMR** (63 MHz, CDCl₃): 166.8, 143.3, 139.1, 136.5, 134.0, 128.7, 128.4, 127.3, 124.2, 51.7, 33.6, 33.0, 32.0, 21.1. **IR** (neat): 2950 (s), 1721 (s), 1639 (s), 1525 (w), 1436 (s), 1308 (s), 1267 (s), 1168 (s), 1038 (m), 987 (m), 865 (w), 766 (m). **R_f** (*n*-hexane/EtOAc, 3:1) = 0.75. **HRMS**: calcd for C₁₄H₁₈BrO₂ [M+H]⁺ 297.0485; found 297.0486.

Methyl (2E)-3-[2-(3-bromopropyl)-6-methoxyphenyl]prop-2-enoate (2c)

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 430 mg (69%); colourless oil.

¹H NMR (250 MHz, CDCl₃): 7.86 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 7.24 (m, 1H, aryl-H), 6.89 – 6.81 (m, 2H, aryl-H), 6.72 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.87 (s, 3H, COOCH₃),

3.81 (s, 3H, OCH₃), 3.40 (t, *J* = 6.5 Hz, 2H, CH₂-Br), 2.93 (t, *J* = 7.3 Hz, 2H, CH₂-CH₂-CH₂-Br), 2.12 (m, 2H, CH₂-CH₂-Br). **¹³C NMR** (63 MHz, CDCl₃): 168.3, 159.4, 142.3, 138.2, 130.2, 122.6, 122.5, 121.9, 109.3, 55.5, 51.6, 33.9, 32.9, 32.1. **IR** (neat): 2948 (m), 2839 (w), 1714 (s), 1627 (s), 1595 (s), 1573 (m), 1470 (s), 1436 (s), 1312 (s), 1266 (s), 1193 (s), 1167 (s), 1075 (s), 986 (m), 948 (w), 869 (w), 791 (m), 756 (m). **R_f** (*n*-hexane/EtOAc, 3:1) = 0.60. **HRMS**: calcd for C₁₄H₁₈BrO₃ [M+H]⁺ 313.0434: found 313.0434.

Methyl (2*E*)-3-[2-(3-bromopropyl)-6-(trifluoromethyl)phenyl]prop-2-enoate (2d)

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 310 mg (44%); colourless oil.

¹H NMR (250 MHz, CDCl₃): 7.88 (dd, *J* = 1.8 Hz, 16.3 Hz, 1H, aryl-CH=CH), 7.58 (d, *J* = 8 Hz, 1H, aryl-H), 7.47 – 7.35 (m, 2H, aryl-H), 6.05 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.83 (s, 3H, COOCH₃), 3.38 (t, *J* = 6.5 Hz, 2H, CH₂-Br), 2.84 (t, *J* = 7.3 Hz, 2H, CH₂-CH₂-CH₂-Br), 2.08 (m, 2H, CH₂-CH₂-Br). **¹³C NMR** (63 MHz, CDCl₃): 166.0, 140.6, 140.2, 132.96, 132.95, 128.2, 126.3, 126.2, 124.3, 124.2, 51.9, 33.3, 32.6, 31.6. **¹⁹F NMR** (282 MHz, CDCl₃): - 58.2. **IR** (neat): 2953 (m), 1726 (s), 1652 (m), 1600 (w), 1458 (m), 1437 (m), 1320 (s), 1280 (s), 1163 (s), 1125 (s), 1038 (m), 1010 (m), 981 (m), 865 (w), 804 (m), 764 (m), 719 (w). **R_f** (*n*-hexane/EtOAc, 3:1) = 0.65. **HRMS**: calcd for C₁₄H₁₅BrF₃O₂ [M+H]⁺ 351.0202: found 351.0201.

Methyl (2*E*)-3-[2-(3-bromopropyl)-6-phenylphenyl]prop-2-enoate (2e)

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 379 mg (53%); yellow oil.

¹H NMR (250 MHz, CDCl₃): 7.76 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 7.37 – 7.19 (m, 8H, aryl-H), 5.66 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 3.69 (s, 3H, COOCH₃), 3.43 (t, *J* = 6.5 Hz, 2H, CH₂-Br), 2.93 (t, *J* = 7.5 Hz, 2H, CH₂-CH₂-CH₂-Br), 2.12 (m, 2H, CH₂-CH₂-Br). **¹³C NMR** (63 MHz, CDCl₃): 166.7, 142.9, 142.4, 141.2, 139.7, 132.7, 129.7, 128.9, 128.5, 128.2, 127.2, 124.8, 51.6, 33.7, 33.0, 32.1. **IR** (neat): 3057 (m), 3023 (m), 2949 (m), 1719 (s), 1637 (m), 1572 (w), 1496 (w), 1458 (m), 1436 (s), 1309 (s), 1270 (s), 1234 (m), 1195 (s), 1170 (s), 1073 (w), 1037 (m), 983 (m), 865 (w), 801 (m), 763 (s), 702 (s). **R_f** (*n*-hexane/EtOAc, 3:1) = 0.70. **HRMS**: calcd for C₁₉H₂₀BrO₂ [M+H]⁺ 359.0641: found 359.0642.

Methyl (2*E*)-3-[2-(3-bromopropyl)naphthalen-1-yl]prop-2-enoate (2f)

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 597 mg (90%); yellow oil.

¹H NMR (250 MHz, CDCl₃): 8.20 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 8.03 (m, 1H, aryl-H), 7.85 – 7.77 (m, 2H, aryl-H), 7.53 – 7.43 (m, 2H, aryl-H), 7.38 (d, *J* = 8.5 Hz, 1H, aryl-H), 6.23 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.88 (s, 3H, COOCH₃), 3.42 (t, *J* = 6.5 Hz, 2H, CH₂-Br),

2.99 (t, J = 7.8 Hz, 2H, $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-Br}$), 2.18 (m, 2H, $\text{CH}_2\text{-CH}_2\text{-Br}$). ^{13}C NMR (63 MHz, CDCl_3): 166.7, 142.5, 136.4, 132.3, 131.3, 131.1, 128.9, 128.2, 127.5, 126.6, 125.8, 125.5, 124.9, 51.8, 33.8, 32.9, 32.1. IR (neat): 3052 (m), 2950 (m), 1721 (s), 1641 (m), 1508 (w), 1435 (m), 1272 (s), 1171 (s), 1037 (m), 986 (m), 865 (w), 818 (m), 751 (m). R_f (n -hexane/EtOAc, 3:1) = 0.65. HRMS: calcd for $\text{C}_{17}\text{H}_{17}\text{BrO}_2\text{Na}$ $[\text{M}+\text{Na}]^+$ 355.0304: found 355.0307.

Methyl (2E)-3-[2-(3-bromopropyl)anthracen-1-yl]prop-2-enoate (2g)

Eluent for column chromatography: n -hexane/EtOAc, 50:1 $\rightarrow$ 25:1.

Yield: 585 mg (76%); yellow solid after recrystallization from MeCN.

^1H NMR (250 MHz, CDCl_3): 8.54 (s, 1H, aryl-H), 8.40 (s, 1H, aryl-H), 8.32 (d, J = 16.3 Hz, 1H, aryl-CH=CH), 8.02 – 7.93 (m, 3H, aryl-H), 7.51 – 7.45 (m, 2H, aryl-H), 7.35 (d, J = 8.8 Hz, 1H, aryl-H), 6.35 (d, J = 16.5 Hz, 1H, aryl-CH=CH), 3.92 (s, 3H, COOCH_3), 3.45 (t, J = 6.5 Hz, 2H, $\text{CH}_2\text{-Br}$), 3.03 (t, J = 7.3 Hz, 2H, $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-Br}$), 2.22 (m, 2H, $\text{CH}_2\text{-CH}_2\text{-Br}$). ^{13}C NMR (63 MHz, CDCl_3): 166.9, 142.6, 136.0, 132.1, 131.3, 130.7, 130.5, 129.7, 129.3, 128.5, 127.8, 127.4, 126.7, 125.76, 125.75, 125.7, 123.8, 51.9, 33.9, 32.9, 32.3. IR (neat): 2945 (w), 1710 (s), 1634 (w), 1455 (w), 1437 (m), 1321 (w), 1264 (s), 1193 (m), 1166 (m), 1133 (w), 1038 (s), 981 (m), 877 (s), 858 (m), 803 (w), 739 (s), 715 (m), 653 (w), 619 (w), 554 (m). mp: 74 – 77 °C. R_f (n -hexane/EtOAc, 3:1) = 0.55. HRMS: calcd for $\text{C}_{21}\text{H}_{19}\text{BrO}_2$ $[\text{M}]^+$ 382.0563: found 382.0561.

Methyl (2E)-3-[10-(3-bromopropyl)phenanthren-9-yl]prop-2-enoate (2h)

Eluent for column chromatography: n -hexane/EtOAc 25:1, $\rightarrow$ 10:1.

Yield: 219 mg (29%); colourless solid after recrystallization from DCM/ n -hexane.

^1H NMR (250 MHz, CDCl_3): 8.76 – 8.69 (m, 2H, aryl-H), 8.26 (d, J = 16.3 Hz, 1H, aryl-CH=CH), 8.17 (m, 1H, aryl-H), 8.00 (m, 1H, aryl-H), 7.70 – 7.55 (m, 4H, aryl-H), 6.23 (d, J = 16.3 Hz, 1H, aryl-CH=CH), 3.90 (s, 3H, COOCH_3), 3.55 (t, J = 6.5 Hz, 2H, $\text{CH}_2\text{-Br}$), 3.34 (t, J = 8 Hz, 2H, $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-Br}$), 2.23 (m, 2H, $\text{CH}_2\text{-CH}_2\text{-Br}$). ^{13}C NMR (63 MHz, CDCl_3): 166.6, 144.0, 133.1, 130.7, 130.6, 130.3, 130.0, 129.7, 127.2, 126.9, 126.5, 126.3, 126.1, 124.8, 123.2, 122.8, 110.0, 51.9, 33.5, 33.2, 28.8 ppm. IR (KBr): 3072 (w), 2951 (w), 1717 (s), 1639 (m), 1493 (w), 1432 (m), 1322 (m), 1270 (s), 1176 (s), 1035 (w), 1006 (w), 758 (s), 726 (m). mp: 93 – 96 °C. R_f (n -hexane/EtOAc, 3:1) = 0.65. HRMS: calcd for $\text{C}_{21}\text{H}_{19}\text{BrO}_2$ $[\text{M}]^+$ 382.0563: found 382.0569.

Methyl (2E)-3-[2-(3-bromopropyl)pyren-1-yl]prop-2-enoate (2i)

Eluent for column chromatography: n -hexane/EtOAc 25:1, $\rightarrow$ 10:1.

Yield: 562 mg (69%); yellow solid after recrystallization from MeCN.

¹H NMR (250 MHz, CDCl₃): 8.43 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 8.33 (d, *J* = 9.5 Hz, 1H, aryl-H), 8.18 (d, *J* = 7.5 Hz, 2H, aryl-H), 8.10 – 7.97 (m, 5H, aryl-H), 6.38 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.93 (s, 3H, COOCH₃), 3.48 (t, *J* = 6.5 Hz, 2H, CH₂-Br), 3.25 (t, *J* = 7.3 Hz, 2H, CH₂-CH₂-CH₂-Br), 2.31 (m, 2H, CH₂-CH₂-Br). **¹³C NMR** (63 MHz, CDCl₃): 166.8, 142.8, 136.6, 131.4, 131.1, 130.5, 129.5, 129.2, 128.3, 128.2, 127.0, 126.3, 126.0, 125.8, 125.6, 125.3, 124.6, 124.4, 123.7, 51.9, 34.0, 33.0, 32.6. **IR** (KBr): 2927 (m), 2857 (w), 1721 (s), 1638 (m), 1596 (w), 1437 (m), 1285 (s), 1200 (m), 1171 (s), 988 (m), 884 (m), 842 (s), 763 (m), 713 (m), 671 (w), 604 (w). **mp**: 121 – 124 °C. **R_f** (*n*-hexane/EtOAc, 3:1) = 0.60. **Elementary analysis**: calcd for C₂₃H₁₉BrO₂ (407.30): C 67.82, H 4.70; found C 67.56, H 4.76.

Methyl (2*E*)-3-[2-(3-bromopropyl)-1-[(4-methylbenzene)sulfonyl]-1*H*-indol-3-yl]prop-2-enoate (2j)

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1 → 5:1.

Yield: 71 mg (7%) (calculated from the ¹H NMR with mesitylene as standard); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 8.25 (m, 1H, aryl-H), 7.88 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 7.78 (m, 1H, aryl-H), 7.62 (d, *J* = 8.3 Hz, 2H, aryl-H), 7.40 – 7.29 (m, 2H, aryl-H), 7.21 (d, *J* = 8 Hz, 2H, aryl-H), 6.54 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.82 (s, 3H, COOCH₃), 3.48 (t, *J* = 6.5 Hz, 2H, CH₂-Br), 3.33 (t, *J* = 7.3 Hz, 2H, CH₂-CH₂-CH₂-Br), 2.35 (s, 3H, CH₃), 2.32 (m, 2H, CH₂-CH₂-Br). **¹³C NMR** (63 MHz, CDCl₃): 167.6, 145.4, 142.4, 137.0, 135.3, 130.1, 127.4, 126.3, 125.2, 124.5, 120.1, 118.9, 117.1, 115.3, 105.0, 51.7, 33.7, 32.7, 25.4, 21.6. **IR** (KBr): 2951 (m), 2371 (w), 1715 (s), 1632 (s), 1447 (m), 1372 (s), 1279 (s), 1232 (m), 1175 (s), 1121 (m), 1088 (m), 1008 (m), 978 (m), 850 (w), 812 (w), 746 (m), 681 (m), 657 (w), 574 (s). **mp**: 104 – 106 °C. **R_f** (*n*-hexane/EtOAc, 3:1) = 0.55. **MS (ESI)**: calcd for C₂₂H₂₂BrNO₄S [M]⁺ 475.05, found 396.5 (100.00) [M-Br]⁺, 476.4 (42.95) [M+H]⁺, 498.4 (75.62) [M+Na]⁺.

General procedure for the substitution reaction with HNBoc₂ (3a-i); GP3:

The alkyl bromide **2a-i** (1 equiv), Cs₂CO₃ (2 equiv; for **2a** 3 equiv) and HNBoc₂ (1.1 equiv; for **2a** 2.1 equiv) were dissolved in dry DMF in a sealable tube and heated to 90 °C overnight.

For workup H₂O was added and the reaction mixture was extracted with EtOAc (3x). The combined organic layers were dried over MgSO₄, concentrated in vacuo and purified by column chromatography.

Methyl (2*E*)-3-[2,6-bis(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)phenyl]prop-2-enoate (3a)

Following GP3 using bromide **2a** (904 mg; 2.24 mmol), Cs₂CO₃ (2.19 g; 6.72 mmol) and HNBoc₂ (1.02 g; 4.70 mmol) in dry DMF (10 mL).

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 1.51 g (99%); colourless oil.

¹H NMR (250 MHz, CDCl₃): 7.84 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 7.23 – 7.06 (m, 3H, aryl-H), 6.00 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 3.80 (s, 3H, COOCH₃), 3.58 (t, *J* = 7.5 Hz, 4H, CH₂-NBoc₂), 2.61 (t, *J* = 7.8 Hz, 4H, CH₂-CH₂-CH₂-NBoc₂), 1.81 (m, 4H, CH₂-CH₂-NBoc₂), 1.48 (s, 36H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 166.4, 152.5, 143.4, 139.8, 133.9, 128.3, 126.9, 124.5, 82.1, 51.6, 46.2, 30.9, 30.1, 28.1. **IR** (neat): 2979 (s), 1789 (m), 1726 (s), 1696 (s), 1642 (w), 1456 (m), 1393 (s), 1367 (s), 1303 (s), 1170 (s), 1138 (s), 1113 (s), 1041 (w), 983 (w), 888 (w), 855 (m), 763 (m). **R_f** (*n*-hexane/EtOAc, 3:1) = 0.50. **HRMS**: calcd for C₃₆H₅₆N₂O₁₀Na [M+Na]⁺ 699.3827; found 699.3821.

Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)-6-methylphenyl]prop-2-enoate (3b)

Following GP3 using bromide **2b** (300 mg; 1.01 mmol), Cs₂CO₃ (658 mg; 2.02 mmol) and HNBoc₂ (241 mg; 1.11 mmol) in dry DMF (5 mL).

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 421 mg (96%); colourless oil.

¹H NMR (250 MHz, CDCl₃): 7.84 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 7.16 (m, 1H, aryl-H), 7.13 – 7.05 (m, 2H, aryl-H), 6.04 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 3.81 (s, 3H, COOCH₃), 3.59 (t, *J* = 7.5 Hz, 2H, CH₂-NBoc₂), 2.64 (t, *J* = 7.8 Hz, 2H, CH₂-CH₂-CH₂-NBoc₂), 2.32 (s, 3H, CH₃), 1.83 (m, 2H, CH₂-CH₂-NBoc₂), 1.48 (s, 18H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 166.8, 152.5, 143.5, 140.0, 136.3, 133.9, 128.4, 128.3, 126.8, 124.1, 82.1, 51.6, 46.2, 30.9, 30.1, 28.0, 21.1. **IR** (neat): 2979 (m), 1789 (w), 1724 (s), 1697 (s), 1640 (w), 1525 (w), 1458 (m), 1438 (m), 1393 (m), 1367 (s), 1306 (s), 1270 (m), 1170 (s), 1137 (s), 1111 (s), 1039 (w), 986 (w), 856 (m), 763 (m). **R_f** (*n*-hexane/EtOAc, 3:1) = 0.65. **HRMS**: calcd for C₂₄H₃₅NO₆Na [M+Na]⁺ 456.2357; found 456.2370.

Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)-6-methoxyphenyl]prop-2-enoate (3c)

Following GP3 using bromide **2c** (566 mg; 1.81 mmol), Cs₂CO₃ (1.18 g; 3.62 mmol) and HNBoc₂ (432 mg; 1.99 mmol) in dry DMF (12 mL).

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 697 mg (86%); colourless oil.

¹H NMR (250 MHz, CDCl₃): 7.85 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 7.21 (m, 1H, aryl-H), 6.81 (m, 2H, aryl-H), 6.67 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.85 (s, 3H, COOCH₃), 3.79 (s, 3H, OCH₃), 3.60 (t, *J* = 7.5 Hz, 2H, CH₂-NBoc₂), 2.75 (t, *J* = 7.8 Hz, 2H, CH₂-CH₂-CH₂-NBoc₂), 1.85 (m, 2H, CH₂-CH₂-NBoc₂), 1.46 (s, 18H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 168.1, 159.2, 152.4, 143.2, 138.3, 130.1, 122.5, 122.1, 109.0, 82.1, 81.9, 55.4, 51.5, 46.1, 31.0, 30.3, 28.0. **IR** (neat): 2979 (m), 1791 (m), 1716 (s), 1628 (m), 1595 (m), 1574 (m), 1471 (m), 1393 (m), 1367 (s), 1310 (m), 1264 (s), 1168 (s), 1137 (s), 1112 (s), 1041 (w), 986 (w), 853 (m), 784

(m), 757 (m). R_f (*n*-hexane/EtOAc, 3:1) = 0.50. **HRMS**: calcd for $C_{24}H_{35}NO_7K$ $[M+K]^+$ 488.2045; found 488.2032.

Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)-6-(trifluoromethyl)phenyl]prop-2-enoate (3d)

Following GP3 using bromide **2d** (285 mg; 0.81 mmol), Cs_2CO_3 (528 mg; 1.62 mmol) and $HNBoc_2$ (193 mg; 0.89 mmol) in dry DMF (6 mL).

Eluent for column chromatography: *n*-hexane/EtOAc, 10:1.

Yield: 359 mg (91%); colourless oil.

1H NMR (250 MHz, $CDCl_3$): 7.87 (dd, J = 1.5 Hz, 16.3 Hz, 1H, aryl-CH=CH), 7.55 (d, J = 7.3 Hz, 1H, aryl-H), 7.44 – 7.33 (m, 2H, aryl-H), 6.03 (d, J = 16.3 Hz, 1H, aryl-CH=CH), 3.82 (s, 3H, $COOCH_3$), 3.59 (t, J = 7.3 Hz, 2H, CH_2-NBoc_2), 2.65 (t, J = 7.8 Hz, 2H, $CH_2-CH_2-CH_2-NBoc_2$), 1.83 (m, 2H, $CH_2-CH_2-NBoc_2$), 1.48 (s, 18H, *t*-Bu). **^{13}C NMR** (63 MHz, $CDCl_3$): 166.0, 152.5, 141.1, 140.8, 133.7, 132.5, 128.1, 126.10, 126.07, 123.94, 123.85, 82.3, 51.8, 46.0, 30.5, 29.8, 28.0. **^{19}F NMR** (282 MHz, $CDCl_3$): - 58.1. **IR** (neat): 2980 (m), 1795 (m), 1730 (s), 1654 (s), 1458 (m), 1394 (m), 1368 (s), 1319 (s), 1139 (s), 1041 (w), 981 (w), 853 (m), 806 (w), 764 (w). R_f (*n*-hexane/EtOAc, 3:1) = 0.60. **HRMS**: calcd for $C_{24}H_{32}F_3NO_6Na$ $[M+Na]^+$ 510.2074; found 510.2066.

Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)-6-phenylphenyl]prop-2-enoate (3e)

Following GP3 using bromide **2e** (367 mg; 1.02 mmol), Cs_2CO_3 (665 mg; 2.04 mmol) and $HNBoc_2$ (243 mg; 1.12 mmol) in dry DMF (7 mL).

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 454 mg (90%); colourless oil.

1H NMR (250 MHz, $CDCl_3$): 7.73 (d, J = 16.3 Hz, 1H, aryl-CH=CH), 7.39 – 7.29 (m, 5H, aryl-H), 7.23 – 7.16 (m, 3H, aryl-H), 5.67 (d, J = 16.3 Hz, 1H, aryl-CH=CH), 3.69 (s, 3H, $COOCH_3$), 3.63 (t, J = 7.5 Hz, 2H, CH_2-NBoc_2), 2.75 (t, J = 8 Hz, 2H, $CH_2-CH_2-CH_2-NBoc_2$), 1.89 (m, 2H, $CH_2-CH_2-NBoc_2$), 1.48 (s, 18H, *t*-Bu). **^{13}C NMR** (63 MHz, $CDCl_3$): 166.6, 152.5, 143.1, 142.3, 141.3, 140.6, 132.6, 129.7, 128.6, 128.49, 128.46, 128.1, 127.1, 124.6, 82.1, 51.5, 46.2, 31.1, 30.2, 28.1. **IR** (neat): 2979 (m), 1790 (m), 1723 (s), 1638 (m), 1458 (m), 1438 (m), 1393 (m), 1367 (s), 1306 (m), 1170 (s), 1138 (s), 1114 (s), 1040 (w), 983 (w), 854 (w), 763 (m), 702 (m). R_f (*n*-hexane/EtOAc, 3:1) = 0.55. **HRMS**: calcd for $C_{29}H_{37}NO_6Na$ $[M+Na]^+$ 518.2513; found 518.2506.

Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)naphthalen-1-yl]prop-2-enoate (3f)

Following GP3 using bromide **2f** (582 mg; 1.75 mmol), Cs₂CO₃ (1.14 g; 3.50 mmol) and HNBoc₂ (419 mg; 1.93 mmol) in dry DMF (8 mL).

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 747 mg (91%); light yellow oil.

¹H NMR (250 MHz, CDCl₃): 8.18 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 8.01 (m, 1H, aryl-H), 7.83 – 7.76 (m, 2H, aryl-H), 7.51 – 7.42 (m, 2H, aryl-H), 7.36 (d, *J* = 8.5 Hz, 1H, aryl-H), 6.22 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.87 (s, 3H, COOCH₃), 3.64 (t, *J* = 7.5 Hz, 2H, CH₂-NBoc₂), 2.82 (t, *J* = 7.8 Hz, 2H, CH₂-CH₂-CH₂-NBoc₂), 1.91 (m, 2H, CH₂-CH₂-NBoc₂), 1.47 (s, 18H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 166.7, 152.5, 142.6, 137.5, 132.2, 131.4, 130.7, 128.8, 128.2, 127.4, 126.5, 125.7, 125.4, 124.9, 82.1, 51.7, 46.2, 31.2, 30.4, 28.0. **IR** (neat): 2979 (s), 1791 (m), 1725 (s), 1642 (m), 1595 (w), 1509 (m), 1479 (m), 1436 (m), 1368 (s), 1299 (s), 1171 (s), 1134 (s), 1042 (m), 986 (m), 856 (m), 819 (m), 754 (m). **R_f** (*n*-hexane/EtOAc, 3:1) = 0.60. **HRMS**: calcd for C₂₇H₃₅NO₆Na [M+Na]⁺ 492.2357; found 492.2373.

Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)anthracen-1-yl]prop-2-enoate (3g)

Following GP3 using bromide **2g** (627 mg; 1.64 mmol), Cs₂CO₃ (1.07 g; 3.28 mmol) and HNBoc₂ (391 mg; 1.80 mmol) in dry DMF (11 mL).

Eluent for column chromatography: *n*-hexane/EtOAc, 50:1 → 25:1 → 10:1.

Yield: 652 mg (77%); yellow solid after recrystallization from MeCN.

¹H NMR (250 MHz, CDCl₃): 8.52 (s, 1H, aryl-H), 8.39 (s, 1H, aryl-H), 8.30 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 8.02 – 7.92 (m, 3H, aryl-H), 7.50 – 7.44 (m, 2H, aryl-H), 7.34 (d, *J* = 8.8 Hz, 1H, aryl-H), 6.33 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.91 (s, 3H, COOCH₃), 3.66 (t, *J* = 7.5 Hz, 2H, CH₂-NBoc₂), 2.86 (t, *J* = 8 Hz, 2H, CH₂-CH₂-CH₂-NBoc₂), 1.95 (m, 2H, CH₂-CH₂-NBoc₂), 1.48 (s, 18H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 166.8, 152.5, 142.8, 137.0, 132.0, 131.2, 130.5, 130.2, 129.8, 129.2, 128.5, 127.8, 127.3, 126.6, 125.7, 125.61, 125.59, 123.7, 82.2, 51.8, 46.3, 31.3, 30.4, 28.1. **IR** (neat): 2987 (w), 1747 (m), 1712 (s), 1641 (w), 1462 (w), 1368 (m), 1292 (m), 1273 (m), 1164 (s), 1126 (s), 1106 (s), 983 (m), 885 (m), 861 (m), 806 (w), 780 (m), 745 (s), 714 (w), 622 (w). **mp**: 91 – 94 °C. **R_f** (*n*-hexane/EtOAc, 3:1) = 0.65. **HRMS**: calcd for C₃₁H₃₇NO₆Na [M+Na]⁺ 542.2513; found 542.2506.

Methyl (2E)-3-[10-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)phenanthren-9-yl]prop-2-enoate (3h)

Following GP3 using bromide **2h** (411 mg; 1.07 mmol), Cs₂CO₃ (697 mg; 2.14 mmol) and HNBoc₂ (256 mg; 1.18 mmol) in dry DMF (8 mL).

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 448 mg (81%); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 8.72 (m, 2H, aryl-H), 8.24 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 8.11 (m, 1H, aryl-H), 7.99 (dd, *J* = 1 Hz, 7.8 Hz, 1H, aryl-H), 7.70 – 7.54 (m, 4H, aryl-H), 6.22 (d, *J* = 16.5 Hz, 1H, aryl-CH=CH), 3.89 (s, 3H, COOCH₃), 3.75 (t, *J* = 7.3 Hz, 2H, CH₂-NBoc₂), 3.16 (t, *J* = 8.3 Hz, 2H, CH₂-CH₂-CH₂-NBoc₂), 1.96 (m, 2H, CH₂-CH₂-NBoc₂), 1.49 (s, 18H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 166.5, 152.5, 144.0, 133.9, 130.6, 130.3, 130.2, 130.1, 129.6, 127.0, 126.79, 126.76, 126.3, 126.2, 126.0, 124.9, 123.2, 122.7, 82.2, 51.8, 46.4, 30.0, 28.0, 27.5. **IR** (neat): 2977 (s), 1785 (m), 1725 (s), 1643 (m), 1525 (w), 1440 (m), 1364 (s), 1267 (s), 1170 (s), 1138 (s), 1042 (m), 988 (w), 856 (m), 755 (s). **mp**: 81 – 84 °C. **R_f** (*n*-hexane/EtOAc, 3:1) = 0.55. **HRMS**: calcd for C₃₁H₃₇NO₆Na [M+Na]⁺ 542.2513; found 542.2505.

Methyl (2*E*)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)pyren-1-yl] prop-2-enoate (3i)

Following GP3 using bromide **2i** (418 mg; 1.03 mmol), Cs₂CO₃ (671 mg; 2.06 mmol) and HNBoc₂ (246 mg; 1.13 mmol) in dry DMF (8 mL).

Eluent for column chromatography: *n*-hexane/EtOAc, 25:1 → 10:1.

Yield: 553 mg (99%); yellow solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 8.42 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 8.33 (d, *J* = 9.3 Hz, 1H, aryl-H), 8.18 (d, *J* = 7.8 Hz, 2H, aryl-H), 8.10 – 7.96 (m, 5H, aryl-H), 6.37 (d, *J* = 16.3 Hz, 1H, aryl-CH=CH), 3.91 (s, 3H, COOCH₃), 3.72 (t, *J* = 7.5 Hz, 2H, CH₂-NBoc₂), 3.09 (t, *J* = 8 Hz, 2H, CH₂-CH₂-CH₂-NBoc₂), 2.07 (m, 2H, CH₂-CH₂-NBoc₂), 1.47 (s, 18H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 166.7, 152.6, 142.9, 137.6, 131.3, 131.0, 130.4, 129.4, 129.0, 128.1, 128.0, 127.0, 126.1, 125.9, 125.4, 125.2, 124.5, 124.431, 124.426, 123.5, 82.1, 51.8, 46.3, 31.6, 30.5, 28.0. **IR** (KBr): 2978 (m), 2869 (w), 1749 (s), 1712 (s), 1629 (w), 1598 (w), 1443 (m), 1364 (s), 1306 (s), 1264 (s), 1136 (s), 1033 (m), 987 (w), 887 (w), 855 (m), 777 (m), 717 (w), 688 (w). **mp**: 130 – 132 °C. **R_f** (*n*-hexane/EtOAc, 3:1) = 0.50. **HRMS**: calcd for C₃₃H₃₇NO₆ [M]⁺ 543.2615; found 543.2619.

General procedure for the conversion to the carboximides (5a-i); GP4:

The starting material was dissolved in MeOH (or in some cases in a mixture of MeOH and EtOAc). After addition of palladium on activated carbon (10% Pd basis, moistened with water; 20 wt-%) the reaction mixture was stirred under a H₂ atmosphere for 8 h. The catalyst was removed by filtration over Celite® and the solvent was removed under reduced pressure.

The crude product was dissolved in MeOH and an aq NaOH solution (8 M; 1:1, v/v) was added. The reaction mixture was stirred at room temperature overnight.

For workup the solution was acidified with HCl (4 M) under ice cooling and extracted with DCM (3x). After drying over MgSO₄ the solvent was removed under reduced pressure.

The crude carboxylic acid was dissolved in dry THF under an argon atmosphere and cooled to -78 °C. Pivaloylchloride (1.2 equiv) and NEt₃ (1.5 equiv) were added which led to the formation of a colourless precipitate. The mixture was stirred at -78 °C for 15 min and at 0 °C for 45 min.

In a second flask (*R*)-4-benzyl-2-oxazolidinone (2 equiv) was dissolved in THF under an argon atmosphere and cooled to -78 °C. After dropwise addition of *n*-butyllithium (1.6 M in hexane; 1.9 equiv), it was stirred at -78 °C for approximately 30 min.

After 45 min at 0 °C the activated carboxylic acid was again cooled to -78 °C and the lithiated oxazolidinone was added. The reaction mixture was then allowed to warm to room temperature overnight.

For workup diluted NaHCO₃ solution was added and it was extracted with DCM (3x). The combined organic phases were washed with diluted NaHCO₃-solution and with brine, dried over MgSO₄ and concentrated under reduced pressure. The product was purified by column chromatography.

***tert*-Butyl *N*-[3-(2-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}-3-(3-[[*tert*-butoxy)carbonyl]amino]propyl)phenyl)propyl] carbamate (5a)**

Following GP4 using methylester **3a** (2.07 g; 3.06 mmol), Pd/C (414 mg), MeOH (30 mL); NaOH (8 M; 20 mL), MeOH (20 mL); Piv-Cl (452 µL; 3.67 mmol), NEt₃ (640 µL; 4.59 mmol), dry THF (34 mL), (*R*)-4-benzyl-2-oxazolidinone (1.08 g; 6.12 mmol), *n*-BuLi (1.6 M in *n*-hexane; 3.63 mL; 5.81 mmol), dry THF (17 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 3:1 → 1:1.

Yield: 1.38 g (72% over 3 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 7.39 – 7.29 (m, 3H, aryl-H), 7.25 – 7.22 (m, 2H, aryl-H), 7.14 – 7.01 (m, 3H, aryl-H), 4.76 – 4.61 (m, 3H, CH + NH), 4.29 – 4.17 (m, 2H, CH₂-O), 3.37 (dd, *J* = 3.3 Hz, 13.3 Hz, 1H, CHH-phenyl), 3.21 (m, 4H, CH₂-NH-Boc), 3.13 – 2.97 (m, 4H, CH₂-CO + CH₂-CH₂-CO), 2.81 (dd, *J* = 9.8 Hz, 13.3 Hz, 1H, CHH-phenyl), 2.69 (t, *J* = 7.8 Hz, 4H, CH₂-CH₂-CH₂-NH-Boc), 1.79 (m, 4H, CH₂-CH₂-NH-Boc), 1.44 (s, 18H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 172.4, 156.0, 153.5, 140.3, 135.9, 135.3, 129.4, 129.0, 127.5, 127.4, 126.6, 79.1, 66.4, 55.3, 40.8, 38.0, 36.4, 31.9, 30.3, 28.4, 23.6. **IR** (neat): 3370 (m), 2972 (m), 1788 (s), 1702 (m), 1683 (s), 1519 (s), 1445 (w), 1395 (m), 1366 (s), 1294 (m), 1249 (m), 1216 (s), 1166 (s), 1119 (m), 1058 (m), 870 (w), 782 (w), 757 (w), 733 (w), 699 (m), 599 (m). **mp**: 126 – 128 °C. ***R*_f** (*n*-hexane/EtOAc, 2:1) = 0.25. **[α]_D²⁰** = -55.5° (*c* = 0.94, MeOH). **HRMS**: calcd for C₃₅H₄₉N₃O₇K [M+K]⁺ 662.3202: found 662.3198.

***tert*-Butyl *N*-[3-(2-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}-3-methylphenyl)propyl]carbamate (5b)**

Following GP4 using methylester **3b** (362 mg; 0.83 mmol), Pd/C (72 mg), MeOH (8 mL); NaOH (8 M; 5 mL), MeOH (5 mL); Piv-Cl (123 µL; 1.00 mmol), NEt₃ (174 µL; 1.25 mmol), dry

THF (9 mL), (*R*)-4-benzyl-2-oxazolidinone (294 mg; 1.66 mmol), *n*-BuLi (1.6 M in *n*-hexane; 988 μ L; 1.58 mmol), dry THF (4.5 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 3:1 $\rightarrow$ 1:1.

Yield: 321 mg (80% over 3 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 7.39 – 7.29 (m, 3H, aryl-H), 7.25 – 7.22 (m, 2H, aryl-H), 7.11 – 7.00 (m, 3H, aryl-H), 4.76 – 4.64 (m, 2H, CH + NH), 4.28 – 4.16 (m, 2H, CH₂-O), 3.36 (dd, *J* = 3.3 Hz, 13.5 Hz, 1H, CHH-phenyl), 3.21 (t, *J* = 7 Hz, 2H, CH₂-NH-Boc), 3.14 – 2.98 (m, 4H, CH₂-CO + CH₂-CH₂-CO), 2.82 (dd, *J* = 9.5 Hz, 13.5 Hz, 1H, CHH-phenyl), 2.69 (t, *J* = 7.8 Hz, 2H, CH₂-CH₂-CH₂-NH-Boc), 2.37 (s, 3H, CH₃), 1.79 (m, 2H, CH₂-CH₂-NH-Boc), 1.45 (s, 9H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 172.6, 156.0, 153.4, 139.9, 136.7, 136.4, 135.3, 129.4, 129.0, 128.5, 127.4, 127.2, 126.4, 79.1, 66.3, 55.2, 40.7, 38.0, 35.4, 31.9, 30.2, 28.4, 24.0, 19.9. **IR** (neat): 3374 (w), 2981 (m), 1788 (s), 1760 (m), 1706 (s), 1680 (s), 1513 (s), 1394 (m), 1365 (m), 1299 (m), 1274 (m), 1229 (m), 1209 (m), 1186 (s), 1164 (s), 1120 (m), 1098 (m), 1049 (m), 991 (m), 978 (m), 866 (w), 780 (m), 761 (s), 735 (s), 701 (s), 676 (m), 593 (m), 511 (w). **mp**: 55 – 57 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.40. **[α]_D²⁰** = -63.2° (*c* = 1.09, MeOH). **HRMS**: calcd for C₂₈H₃₆N₂O₅K [M+K]⁺ 519.2256: found 519.2245.

***tert*-Butyl *N*-[3-(2-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl]-3-methoxyphenyl)propyl]carbamate (5c)**

Following GP4 using methylester **3c** (1.11 g; 2.47 mmol), Pd/C (222 mg), MeOH/EtOAc (3:1; 29 mL); NaOH (8 M; 17 mL), MeOH (17 mL); Piv-Cl (365 μ L; 2.96 mmol), NEt₃ (517 μ L; 3.71 mmol), dry THF (29 mL), (*R*)-4-benzyl-2-oxazolidinone (875 mg; 4.94 mmol), *n*-BuLi (1.6 M in *n*-hexane; 2.93 mL; 4.69 mmol), dry THF (14.5 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 3:1 $\rightarrow$ 1:1.

Yield: 948 mg (77% over 3 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 7.38 – 7.28 (m, 3H, aryl-H), 7.24 – 7.21 (m, 2H, aryl-H), 7.13 (t, *J* = 8 Hz, 1H, aryl-H), 6.77 (d, *J* = 7.8 Hz, 1H, aryl-H), 6.72 (d, *J* = 8.3 Hz, 1H, aryl-H), 4.73 – 4.64 (m, 2H, CH + NH), 4.24 – 4.14 (m, 2H, CH₂-O), 3.82 (s, 3H, OCH₃), 3.35 (dd, *J* = 3.3 Hz, 13.3 Hz, 1H, CHH-phenyl), 3.22 – 3.10 + 3.01 (m, 4H + m, 2H, CH₂-CH₂-CO + CH₂-NH-Boc + CH₂-CO), 2.78 (dd, *J* = 9.8 Hz, 13.3 Hz, 1H, CHH-phenyl), 2.69 (t, *J* = 7.8 Hz, 2H, CH₂-CH₂-CH₂-NH-Boc), 1.77 (m, 2H, CH₂-CH₂-NH-Boc), 1.44 (s, 9H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 173.0, 157.9, 156.0, 153.4, 141.1, 135.4, 129.4, 129.0, 127.3, 127.0, 126.7, 121.7, 108.2, 79.1, 66.2, 55.4, 55.3, 40.7, 38.0, 35.3, 31.7, 30.2, 28.4, 21.0. **IR** (neat): 3369 (m), 2975 (w), 1791 (s), 1694 (s), 1684 (s), 1584 (m), 1530 (m), 1458 (m), 1394 (m), 1368 (m), 1305 (m), 1264 (s), 1216 (s), 1168 (s), 1121 (m), 1104 (m), 1027 (m), 1007 (m), 864 (w), 797 (w), 776 (m), 757 (m), 733 (m), 695 (m), 643 (m), 550 (w), 532 (m), 506 (w). **mp**: 97 – 100 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.35. **[α]_D²⁰** = -59.5° (*c* = 0.55, MeOH). **HRMS**: calcd for C₂₈H₃₆N₂O₆K [M+K]⁺ 535.2205: found 535.2197.

tert-Butyl N-[3-(2-{3-[(4R)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}-3-(trifluoromethyl)phenyl)propyl]carbamate (5d)

Following GP4 using methylester **3d** (1.43 g; 2.93 mmol), Pd/C (286 mg), MeOH (30 mL); NaOH (8 M; 19 mL), MeOH (19 mL); Piv-Cl (434 μ L; 3.52 mmol), NEt₃ (613 μ L; 4.40 mmol), dry THF (33 mL), (*R*)-4-benzyl-2-oxazolidinone (1.04 g; 5.86 mmol), *n*-BuLi (1.6 M in *n*-hexane; 3.48 mL; 5.57 mmol), dry THF (16.5 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 3:1 $\rightarrow$ 1:1.

Yield: 1.06 g (68% over 3 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 7.53 (d, *J* = 7.8 Hz, 1H, aryl-H), 7.39 – 7.29 (m, 5H, aryl-H), 7.24 – 7.21 (m, 2H, aryl-H), 4.78 – 4.61 (m, 2H, CH + NH), 4.30 – 4.18 (m, 2H, CH₂-O), 3.36 (dd, *J* = 3.3 Hz, 13.3 Hz, 1H, CHH-phenyl), 3.26 – 3.09 (m, 6H, CH₂-CO + CH₂-CH₂-CO + CH₂-NH-Boc), 2.84 (dd, *J* = 9.5 Hz, 13.3 Hz, 1H, CHH-phenyl), 2.71 (m, 2H, CH₂-CH₂-CH₂-NH-Boc), 1.81 (m, 2H, CH₂-CH₂-NH-Boc), 1.44 (s, 9H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 171.9, 156.0, 153.5, 142.2, 136.8, 135.2, 133.1, 129.4, 129.0, 127.4, 126.6, 124.4, 124.3, 122.6, 79.3, 66.4, 55.2, 40.5, 37.9, 36.5, 31.8, 29.5, 28.4, 23.4. **¹⁹F NMR** (282 MHz, CDCl₃): -59.2. **IR** (neat): 3675 (w), 3373 (w), 2988 (m), 1785 (m), 1711 (s), 1682 (s), 1524 (m), 1456 (w), 1395 (m), 1373 (m), 1314 (m), 1298 (m), 1242 (m), 1210 (m), 1187 (m), 1151 (m), 1113 (s), 1049 (s), 1009 (m), 977 (w), 879 (w), 797 (w), 763 (m), 735 (m), 700 (s), 590 (w), 508 (w). **mp**: 91 – 94 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.35. **[α]_D²⁰** = -61.7° (*c* = 1.03, MeOH). **HRMS**: calcd for C₂₈H₃₃F₃N₂O₅K [M+K]⁺ 573.1973; found 573.1966.

tert-Butyl N-[3-(2-{3-[(4R)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}-3-phenylphenyl)propyl]carbamate (5e)

Following GP4 using methylester **3e** (1.03 g; 2.08 mmol), Pd/C (206 mg), MeOH (21 mL); NaOH (8 M; 15 mL), MeOH (15 mL); Piv-Cl (308 μ L; 2.50 mmol), NEt₃ (435 μ L; 3.12 mmol), dry THF (25 mL), (*R*)-4-benzyl-2-oxazolidinone (737 mg; 4.16 mmol), *n*-BuLi (1.6 M in *n*-hexane; 2.47 mL; 3.95 mmol), dry THF (12.5 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 3:1 $\rightarrow$ 1:1.

Yield: 796 mg (71% over 3 steps); colourless oil.

¹H NMR (250 MHz, CDCl₃): 7.45 – 7.36 (m, 3H, aryl-H), 7.34 – 7.26 (m, 5H, aryl-H), 7.24 – 7.11 (m, 4H, aryl-H), 7.04 (m, 1H, aryl-H), 4.68 (br s, 1H, NH), 4.58 (m, 1H, CH), 4.20 – 4.09 (m, 2H, CH₂-O), 3.28 – 3.17 (m, 3H, CH₂-NH-Boc + CHH-phenyl), 3.04 – 2.88 (m, 4H, CH₂-CH₂-CO + CH₂-CO), 2.76 – 2.67 (m, 3H, CH₂-CH₂-CH₂-NH-Boc + CHH-phenyl), 1.86 (m, 2H, CH₂-CH₂-NH-Boc), 1.50 + 1.45 (s*, 9H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 172.1, 156.0, 153.3, 143.1, 142.3, 140.1, 135.8, 135.2, 129.3, 129.1, 128.9, 128.7, 128.4, 128.1, 127.3, 126.8, 126.1, 79.1, 66.2, 55.0, 40.6, 37.8, 36.2, 31.9, 30.3, 28.4, 28.0, 23.7. **IR** (neat): 3389 (m), 3060 (m), 3027 (m), 2976 (s), 2931 (s), 2869 (m), 1781 (s), 1698 (s), 1604 (w), 1583 (w), 1516 (s), 1454 (s), 1391 (s), 1366 (s), 1303 (s), 1249 (s), 1213 (s), 1169 (s), 1108 (s), 1074 (m), 1052 (m), 985 (m), 920 (w), 865 (w), 803 (w), 763 (s), 704 (s), 636 (w), 549 (w), 505 (w). **R_f** (*n*-hexane/EtOAc, 2:1) = 0.40. **[α]_D²⁰** = -39.1° (*c* = 1.06, DCM). **HRMS**: calcd for C₃₃H₃₈N₂O₅K [M+K]⁺ 581.2412; found 581.2408.

tert-Butyl N-[3-(1-{3-[(4R)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}naphthalen-2-yl)propyl]carbamate (5f)

Following GP4 using methylester **3f** (889 mg; 1.89 mmol), Pd/C (178 mg), MeOH (19 mL); NaOH (8 M; 12 mL), MeOH (12 mL); Piv-Cl (280 μ L; 2.27 mmol), NEt₃ (396 μ L; 2.84 mmol), dry THF (24 mL), (R)-4-benzyl-2-oxazolidinone (670 mg; 3.78 mmol), *n*-BuLi (1.6 M in *n*-hexane; 2.24 mL; 3.59 mmol), dry THF (12 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 3:1 $\rightarrow$ 1:1.

Yield: 628 mg (64% over 3 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 8.09 (d, *J* = 8.5 Hz, 1H, aryl-H), 7.81 (dd, *J* = 1 Hz, 8 Hz, 1H, aryl-H), 7.69 (d, *J* = 8.5 Hz, 1H, aryl-H), 7.53 (m, 1H, aryl-H), 7.45 (m, 1H, aryl-H), 7.40 – 7.29 (m, 4H, aryl-H), 7.25 – 7.23 (m, 2H, aryl-H), 4.77 – 4.68 (m, 2H, CH + NH), 4.25 – 4.17 (m, 2H, CH₂-O), 3.50 (m, 2H, CH₂-NH-Boc), 3.38 (dd, *J* = 3.3 Hz, 13.3 Hz, 1H, CHH-phenyl), 3.29 – 3.23 (m, 4H, CH₂-CH₂-CO + CH₂-CO), 2.92 – 2.78 (m, 3H, CH₂-CH₂-CH₂-NH-Boc + CHH-phenyl), 1.87 (m, 2H, CH₂-CH₂-NH-Boc), 1.45 (s, 9H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 172.6, 156.0, 153.4, 137.2, 135.3, 132.8, 132.6, 132.1, 129.4, 129.0, 128.7, 128.1, 127.4, 127.1, 126.3, 124.9, 123.5, 79.1, 66.3, 55.3, 40.8, 38.0, 36.4, 32.0, 30.8, 28.4, 23.2. **IR** (neat): 3355 (m), 2972 (w), 1784 (s), 1699 (s), 1679 (s), 1522 (s), 1474 (m), 1442 (w), 1378 (s), 1367 (s), 1347 (m), 1305 (m), 1268 (m), 1239 (m), 1208 (m), 1193 (s), 1171 (s), 1095 (m), 1030 (m), 1018 (w), 1006 (s), 979 (m), 946 (w), 927 (w), 870 (w), 818 (m), 793 (w), 782 (w), 764 (m), 752 (m), 738 (s), 705 (s), 671 (w), 613 (m), 579 (m), 565 (m), 503 (m). **mp**: 105 – 108 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.35. **[α]_D²⁰** = -58.8° (*c* = 0.50, MeOH). **HRMS**: calcd for C₃₁H₃₆N₂O₅K [M+K]⁺ 555.2256: found 555.2249.

tert-Butyl N-[3-(1-{3-[(4R)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}anthracen-2-yl)propyl]carbamate (5g)

Following GP4 using methylester **3g** (294 mg; 0.57 mmol), Pd/C (59 mg), MeOH/EtOAc (2:1; 8 mL); NaOH (8 M; 4 mL), MeOH (4 mL); Piv-Cl (84 μ L; 0.68 mmol), NEt₃ (120 μ L; 0.86 mmol), dry THF (7 mL), (R)-4-benzyl-2-oxazolidinone (202 mg; 1.14 mmol), *n*-BuLi (1.6 M in *n*-hexane; 675 μ L; 1.08 mmol), dry THF (3.5 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 3:1 $\rightarrow$ 1:1.

Yield: 114 mg (35% over 3 steps); yellow solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 8.65 (s, 1H, aryl-H), 8.39 (s, 1H, aryl-H), 8.07 (m, 1H, aryl-H), 7.98 (m, 1H, aryl-H), 7.86 (d, *J* = 8.8 Hz, 1H, aryl-H), 7.49 – 7.42 (m, 2H, aryl-H), 7.39 – 7.23 (m, 6H, aryl-H), 4.79 – 4.70 (m, 2H, CH + NH), 4.26 – 4.17 (m, 2H, CH₂-O), 3.64 + 3.43 – 3.22 (m, 2H + m, 5H, CH₂-NH-Boc + CHH-phenyl + CH₂-CH₂-CO + CH₂-CO), 2.95 – 2.76 (m, 3H, CH₂-CH₂-CH₂-NH-Boc + CHH-phenyl), 1.91 (m, 2H, CH₂-CH₂-NH-Boc), 1.45 (s, 9H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 172.7, 156.1, 153.4, 136.5, 135.3, 132.1, 132.0, 131.1, 130.9, 130.6, 129.4, 129.0, 128.7, 128.0, 127.7, 127.5, 127.4, 126.9, 125.34, 125.28, 122.1, 79.1, 66.3, 55.3, 40.7, 38.0, 36.3, 31.8, 31.0, 28.4, 23.5. **IR** (neat): 3367 (w), 2966 (w), 1790 (s), 1698 (s), 1686 (s), 1537 (s), 1446 (w), 1394 (m), 1365 (m), 1292 (m), 1269 (m), 1250 (m), 1211 (s), 1172 (s), 1121 (m), 1068 (w), 1032 (w), 1000 (m), 879 (m),

760 (m), 737 (s), 724 (m), 701 (m), 643 (m). **mp**: 165 – 167 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.35. **[α]_D²⁰** = -50.0° (c = 0.21, DCM). **HRMS**: calcd for C₃₅H₃₈N₂O₅Na [M+Na]⁺ 589.2673: found 589.2674.

***tert*-Butyl *N*-[3-(10-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl} phenanthren-9-yl)propyl]carbamate (5h)**

Following GP4 using methylester **3h** (1.38 g; 2.66 mmol), Pd/C (276 mg), MeOH/EtOAc (2:1; 26 mL); NaOH (8 M; 17 mL), MeOH (17 mL); Piv-Cl (393 μL; 3.19 mmol), NEt₃ (556 μL; 3.99 mmol), dry THF (30 mL), (*R*)-4-benzyl-2-oxazolidinone (943 mg; 5.32 mmol), *n*-BuLi (1.6 M in *n*-hexane; 3.16 mL; 5.05 mmol), dry THF (15 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 3:1 → 1:1.

Yield: 1.03 g (68% over 3 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 8.75 – 8.70 (m, 2H, aryl-H), 8.18 (m, 1H, aryl-H), 8.10 (m, 1H, aryl-H), 7.70 – 7.60 (m, 4H, aryl-H), 7.40 – 7.25 (m, 5H, aryl-H), 4.87 (br s, 1H, NH), 4.77 (m, 1H, CH), 4.29 – 4.18 (m, 2H, CH₂-O), 3.58 + 3.45 – 3.23 (m, 2H + m, 7H, CH₂-CH₂-CO + CHH-phenyl + CH₂-CO + CH₂-NH-Boc + CH₂-CH₂-CH₂-NH-Boc), 2.86 (dd, *J* = 9.8 Hz, 13.5 Hz, 1H, CHH-phenyl), 1.94 (m, 2H, CH₂-CH₂-NH-Boc), 1.47 (s, 9H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 172.6, 156.1, 153.5, 135.3, 134.0, 131.5, 130.9, 130.8, 130.2, 130.0, 129.4, 129.0, 127.4, 127.0, 126.8, 125.9, 125.8, 124.5, 124.2, 123.1, 123.0, 79.2, 66.4, 55.3, 41.2, 38.0, 36.1, 31.1, 28.4, 26.5, 24.3. **IR** (neat): 3363 (w), 2977 (m), 1783 (s), 1760 (m), 1707 (s), 1677 (s), 1509 (s), 1445 (m), 1394 (s), 1365 (s), 1271 (m), 1238 (m), 1208 (m), 1186 (s), 1167 (s), 1120 (m), 1098 (m), 1047 (m), 993 (m), 977 (m), 864 (w), 752 (s), 735 (m), 724 (s), 701 (m), 669 (w), 592 (m), 509 (w). **mp**: 166 – 168 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.30. **[α]_D²⁰** = -63.6° (c = 0.50, DCM). **HRMS**: calcd for C₃₅H₃₈N₂O₅K [M+K]⁺ 605.2412: found 605.2409.

***tert*-Butyl *N*-[3-(1-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}pyren-2-yl)propyl]carbamate (5i)**

Following GP4 using methylester **3i** (1.54 g; 2.83 mmol), Pd/C (308 mg), MeOH/EtOAc (1:2; 29 mL); NaOH (8 M; 18 mL), MeOH (18 mL); Piv-Cl (419 μL; 3.40 mmol), NEt₃ (592 μL; 4.25 mmol), dry THF (32 mL), (*R*)-4-benzyl-2-oxazolidinone (1.00 g; 5.66 mmol), *n*-BuLi (1.6 M in *n*-hexane; 3.36 mL; 5.38 mmol), dry THF (16 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 3:1 → 1:1.

Yield: 1.30 g (78% over 3 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (250 MHz, CDCl₃): 8.36 (d, *J* = 9.5 Hz, 1H, aryl-H), 8.18 – 8.12 (m, 3H, aryl-H), 8.04 – 7.94 (m, 4H, aryl-H), 7.39 – 7.23 (m, 5H, aryl-H), 4.86 – 4.71 (m, 2H, CH + NH), 4.26 – 4.17 (m, 2H, CH₂-O), 3.76 3.43 – 3.30 (m, 2H + m, 5H, CH₂-CH₂-CO + CHH-phenyl + CH₂-CO + CH₂-NH-Boc), 3.18 (m, 2H, CH₂-CH₂-CH₂-NH-Boc), 2.84 (dd, *J* = 9.8 Hz, 13.5 Hz, 1H, CHH-phenyl), 2.03 (m, 2H, CH₂-CH₂-NH-Boc), 1.46 + 1.43 (s*, 9H, *t*-Bu). **¹³C NMR** (63 MHz, CDCl₃): 172.5, 156.1, 153.4, 138.0, 135.2, 132.3, 131.1, 130.4, 130.1, 129.4,

129.3, 129.0, 127.9, 127.4, 127.2, 127.0, 126.2, 125.6, 125.0, 124.814, 124.805, 123.9, 123.2, 79.1, 66.4, 55.3, 40.8, 38.0, 37.0, 32.4, 31.3, 28.4, 26.9, 23.8. **IR** (neat): 3367 (w), 2929 (w), 1793 (s), 1705 (s), 1677 (s), 1514 (s), 1394 (m), 1364 (m), 1296 (m), 1236 (m), 1208 (m), 1189 (s), 1099 (m), 1044 (m), 1009 (m), 978 (m), 867 (w), 840 (m), 826 (m), 760 (m), 749 (m), 736 (m), 701 (m), 683 (m), 592 (m), 506 (w). **mp**: 157 – 159 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.30. **[α]_D²⁰** = -54.2° (c = 0.20, DCM). **HRMS**: calcd for C₃₇H₃₈N₂O₅ [M]⁺ 590.2775: found 590.2764.

General procedure for the conversion of carboximides 5a-i to the protected amino acids (7a-i); GP5:

Carboximide **5a-i** was dissolved in dry THF and cooled to -78 °C under an argon atmosphere. In a second flask KHMDS (0.5 M in toluene; 2.5 equiv, for **5a** 3.5 equiv) was diluted in dry THF and cooled to -78 °C under an argon atmosphere. The KHMDS solution was added to the carboximide and stirred at -78 °C for 30 min. Then a solution of tris-azide (1.5 equiv) in dry THF cooled to -78 °C was added. After 2 min at -78 °C the reaction was quenched by addition of HOAc (4.6 equiv) and it was warmed to 30 °C in a water bath. After 3 h at 30 °C it was stirred at room temperature overnight.

For workup DCM was added and the organic layer was washed with brine. It was extracted with DCM (3x) and washed with saturated NaHCO₃ solution. After drying over MgSO₄ the crude product was purified by column chromatography (pentane/Et₂O 1:1 → 1:3).

The azide was dissolved in a THF/H₂O solution and cooled to 0 °C. H₂O₂ (30%; 4 equiv) and freshly pestled LiOH (2 equiv) were added. After 2.5 h at 0 °C the reaction was quenched with an aq Na₂S₂O₅ solution (4.4 equiv). Then it was acidified with HCl (4 M) at 0 °C, extracted with EtOAc (3x), dried over Na₂SO₄ and concentrated under reduced pressure.

The intermediate was dissolved in MeOH and treated with Pd/C (10% Pd basis, moistened with water; 20 wt-%) under a H₂ atmosphere for 6 h. The catalyst was removed by filtration over Celite®.

After concentration under reduced pressure the amine was dissolved in a H₂O/dioxane solution (1:1, v/v) and cooled to 0 °C. NaHCO₃ (3 equiv) and a solution of Fmoc-OSu (1.1 equiv) in dioxane was added. Afterwards, the reaction mixture was stirred at room temperature overnight.

For workup it was acidified with HCl (1 M) under ice cooling and extracted with EtOAc (3x). After drying over MgSO₄ the protected amino acid was dissolved in dry DMF. NaHCO₃ (2 equiv) and benzyl bromide (3 equiv) were added and the reaction mixture was stirred at room temperature overnight.

H₂O was added and it was extracted with EtOAc (3x). The combined organic phases were washed with H₂O (2x), dried over MgSO₄ and purified by column chromatography.

Benzyl (2R)-3-[2,6-bis(3-[[*tert*-butoxy)carbonyl]amino}propyl)phenyl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino}propanoate (7a)

Following GP5 using carboximide **5a** (550 mg; 0.88 mmol), KHMDS (0.5 M in toluene; 6.16 mL; 3.08 mmol), tris-azide (408 mg; 1.32 mmol), HOAc (232 μ L; 4.05 mmol), dry THF (3 x 6 mL); isolated azide **6a** (401 mg; 0.60 mmol); H₂O₂ (30%; 245 μ L; 2.40 mmol), LiOH (29 mg; 1.20 mmol), THF (9.2 mL), H₂O (2.7 mL), Na₂S₂O₅ (502 mg; 2.64 mmol; in 1.9 mL H₂O); Pd/C (80 mg), MeOH (7 mL); Fmoc-OSu (223 mg; 0.66 mmol), NaHCO₃ (151 mg, 1.80 mmol), dioxane/H₂O (1:1; 4.7 mL), dioxane (2.3 mL); NaHCO₃ (101 mg; 1.20 mmol), BnBr (214 μ L; 1.80 mmol), dry DMF (7 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 10:1 $\rightarrow$ 5:1 $\rightarrow$ 3:1.

Yield: 281 mg (40% over 5 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (400 MHz, CDCl₃): 7.77 (d, *J* = 7.2 Hz, 2H, aryl-H), 7.61 – 7.58 (m, 2H, aryl-H), 7.42 – 7.28 (m, 7H, aryl-H), 7.11 – 7.01 (m, 3H, aryl-H), 6.97 (d, *J* = 7.6 Hz, 2H, aryl-H), 5.55 (d, *J* = 5.6 Hz, 1H, NH-Fmoc), 5.04 (d, *J* = 12 Hz, 1H, COO-CHH-phenyl), 4.97 (d, *J* = 12.4 Hz, 1H, COO-CHH-phenyl) 4.73 (m, 2H, NH-Boc), 4.56 (q, *J* = 8 Hz, 1H, α -CH), 4.40 (m, 2H, CH₂-fluorenyl), 4.21 (m, 1H, CH-fluorenyl), 3.18 – 3.03 (m, 6H, α -CH-CH₂ + CH₂-NH-Boc), 2.70 – 2.55 (m, 4H, CH₂-CH₂-CH₂-NH-Boc), 1.71 (m, 4H, CH₂-CH₂-NH-Boc), 1.44 + 1.42 (s*, 18H, *t*-Bu). **¹³C NMR** (75 MHz, CDCl₃): 172.1, 156.0, 155.6, 143.8, 143.7, 141.3, 141.0, 134.7, 131.6, 128.6, 128.5, 128.3, 128.2, 127.7, 127.5, 127.2, 127.0, 125.1, 125.0, 120.0, 82.0, 79.0, 67.3, 66.9, 58.5, 54.7, 47.1, 40.4, 32.4, 31.8, 30.2, 28.4. **IR** (neat): 3356 (m), 2979 (w), 1736 (m), 1684 (s), 1520 (s), 1451 (m), 1391 (w), 1366 (m), 1273 (s), 1254 (s), 1239 (s), 1168 (s), 1106 (m), 1091 (m), 1033 (m), 997 (m), 872 (w), 782 (w), 757 (m), 739 (s), 695 (m), 621 (m), 543 (w). **mp**: 149 – 152 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.35. **[α]_D²⁰** = -3.1° (*c* = 0.77, DCM). **HRMS**: calcd for C₄₇H₅₇N₃O₈Na [M+Na]⁺ 814.4038: found 814.4063.

Benzyl (2R)-3-[2-(3-[[*tert*-butoxy)carbonyl]amino}propyl)-6-methylphenyl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino}propanoate (7b)

Following GP5 using carboximide **5b** (231 mg; 0.48 mmol), KHMDS (0.5 M in toluene; 2.40 mL; 1.20 mmol), tris-azide (223 mg; 0.72 mmol), HOAc (126 μ L; 2.21 mmol), dry THF (3 x 3 mL); isolated azide **6b** (100 mg; 0.19 mmol); H₂O₂ (30%; 78 μ L; 0.76 mmol), LiOH (9 mg; 0.38 mmol), THF (2.9 mL), H₂O (0.9 mL), Na₂S₂O₅ (160 mg; 0.84 mmol; in 0.6 mL H₂O); Pd/C (20 mg), MeOH (2 mL); Fmoc-OSu (71 mg; 0.21 mmol), NaHCO₃ (48 mg, 0.57 mmol), dioxane/H₂O (1:1; 1.3 mL), dioxane (0.7 mL); NaHCO₃ (32 mg; 0.38 mmol), BnBr (68 μ L; 0.57 mmol), dry DMF (2 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 10:1 $\rightarrow$ 5:1.

Yield: 56 mg (18% over 5 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (400 MHz, CDCl₃): 7.76 (d, *J* = 7.6 Hz, 2H, aryl-H), 7.58 – 7.52 (m, 2H, aryl-H), 7.40 (t, *J* = 7.2 Hz, 2H, aryl-H), 7.33 – 7.26 (m, 5H, aryl-H), 7.08 – 7.05 (m, 3H, aryl-H), 6.99 – 6.96 (m, 2H, aryl-H), 5.47 (d, *J* = 7.6 Hz, 1H, NH-Fmoc), 5.07 (d, *J* = 12.4 Hz, 1H, COO-CHH-phenyl), 5.00 (d, *J* = 12 Hz, 1H, COO-CHH-phenyl), 4.80 (br s, 1H, NH-Boc), 4.61 (q,

$J = 8$ Hz, 1H, α -CH), 4.36 (d, $J = 6.8$ Hz, 2H, CH_2 -fluorenyl), 4.17 (t, $J = 6.8$ Hz, 1H, CH-fluorenyl), 3.21 – 3.07 (m, 4H, α -CH- CH_2 + CH_2 -NH-Boc), 2.65 (m, 2H, CH_2 - CH_2 - CH_2 -NH-Boc), 2.30 (s, 3H, CH_3), 1.72 (m, 2H, CH_2 - CH_2 -NH-Boc), 1.42 (s, 9H, t -Bu). **^{13}C NMR** (75 MHz, CDCl_3): 172.2, 156.0, 155.6, 143.8, 143.7, 141.3, 140.7, 137.2, 134.8, 132.2, 128.6, 128.5, 128.3, 128.1, 127.7, 127.4, 127.0, 125.1, 120.0, 79.0, 67.3, 67.1, 54.0, 47.1, 40.5, 32.9, 31.8, 30.1, 28.4, 26.9, 20.3. **IR** (neat): 3356 (w), 2979 (w), 1757 (m), 1701 (s), 1682 (s), 1528 (s), 1451 (m), 1390 (w), 1366 (m), 1263 (s), 1214 (m), 1168 (s), 1105 (m), 1089 (m), 1040 (m), 991 (m), 874 (w), 756 (m), 738 (s), 698 (m), 621 (m), 541 (w). **mp**: 94 – 96 °C. **R_f** (n -hexane/EtOAc, 2:1) = 0.40. **$[\alpha]_D^{20}$** = -6.8° ($c = 0.22$, DCM). **HRMS**: calcd for $\text{C}_{40}\text{H}_{44}\text{N}_2\text{O}_6\text{Na}$ $[\text{M}+\text{Na}]^+$ 671.3092: found 671.3091.

Benzyl (2R)-3-[2-(3-[[*tert*-butoxy]carbonyl]amino)propyl]-6-methoxyphenyl]-2-[[*9H*-fluoren-9-ylmethoxy]carbonyl]amino}propanoate (7c)

Following GP5 using carboximide **5c** (433 mg; 0.87 mmol), KHMDS (0.5 M in toluene; 4.36 mL; 2.18 mmol), tris-azide (405 mg; 1.31 mmol), HOAc (229 μL ; 4.00 mmol), dry THF (3 x 6 mL); isolated azide **6c** (273 mg; 0.51 mmol); H_2O_2 (30%; 208 μL ; 2.04 mmol), LiOH (24 mg; 1.02 mmol), THF (7.8 mL), H_2O (2.3 mL), $\text{Na}_2\text{S}_2\text{O}_5$ (426 mg; 2.24 mmol; in 1.6 mL H_2O); Pd/C (55 mg), MeOH (6 mL); Fmoc-OSu (189 mg; 0.56 mmol), NaHCO_3 (129 mg, 1.53 mmol), dioxane/ H_2O (1:1; 4 mL), dioxane (2 mL); NaHCO_3 (86 mg; 1.02 mmol), BnBr (182 μL ; 1.53 mmol), dry DMF (6 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 10:1 $\rightarrow$ 5:1.

Yield: 83 mg (14% over 5 steps); colourless solid after recrystallization from DCM/ n -hexane.

^1H NMR (400 MHz, CDCl_3): 7.75 (d, $J = 7.6$ Hz, 2H, aryl-H), 7.55 – 7.50 (m, 2H, aryl-H), 7.39 (t, $J = 7.6$ Hz, 2H, aryl-H), 7.34 – 7.25 (m, 7H, aryl-H), 7.16 (t, $J = 8$ Hz, 1H, aryl-H), 6.81 (d, $J = 7.6$ Hz, 1H, aryl-H), 6.71 (d, $J = 8.4$ Hz, 1H, aryl-H), 5.79 (d, $J = 7.2$ Hz, 1H, NH-Fmoc), 5.15 (s, 2H, COO-CH_2 -phenyl), 4.67 (br s, 1H, NH-Boc), 4.49 (m, 1H, α -CH), 4.31 (m, 2H, CH_2 -fluorenyl), 4.16 (m, 1H, CH-fluorenyl), 3.78 (s, 3H, OCH_3), 3.20 – 3.07 (m, 4H, α -CH- CH_2 + CH_2 -NH-Boc), 2.65 (m, 2H, CH_2 - CH_2 - CH_2 -NH-Boc), 1.73 (m, 2H, CH_2 - CH_2 -NH-Boc), 1.43 (s, 9H, t -Bu). **^{13}C NMR** (75 MHz, CDCl_3): 172.1, 157.8, 156.0, 155.8, 144.0, 143.8, 142.0, 141.3, 135.4, 128.5, 128.2, 128.0, 127.6, 127.0, 125.1, 122.9, 122.2, 119.9, 108.2, 79.1, 67.0, 66.9, 55.4, 54.8, 47.1, 40.5, 31.5, 29.8, 28.4. **IR** (neat): 3367 (w), 2962 (w), 1750 (m), 1700 (m), 1677 (s), 1584 (w), 1519 (s), 1470 (m), 1448 (m), 1392 (w), 1363 (w), 1269 (s), 1221 (m), 1163 (s), 1108 (m), 1097 (m), 1044 (m), 994 (w), 956 (m), 868 (w), 783 (m), 752 (m), 740 (s), 697 (m), 621 (m), 536 (m). **mp**: 143 – 146 °C. **R_f** (n -hexane/EtOAc, 2:1) = 0.35. **$[\alpha]_D^{20}$** = -4.4° ($c = 0.46$, DCM). **HRMS**: calcd for $\text{C}_{40}\text{H}_{44}\text{N}_2\text{O}_7\text{Na}$ $[\text{M}+\text{Na}]^+$ 687.3041: found 687.3061.

Benzyl (2R)-3-[2-(3-[[*tert*-butoxy]carbonyl]amino)propyl]-6-(trifluoromethyl)phenyl]-2-[[*9H*-fluoren-9-ylmethoxy]carbonyl]amino}propanoate (7d)

Following GP5 using carboximide **5d** (380 mg; 0.71 mmol), KHMDS (0.5 M in toluene; 3.56 mL; 1.78 mmol), tris-azide (331 mg; 1.07 mmol), HOAc (187 μL ; 3.27 mmol), dry THF (3 x 5 mL); isolated azide **6d** (280 mg; 0.49 mmol); H_2O_2 (30%; 200 μL ; 1.96 mmol), LiOH

(23 mg; 0.98 mmol), THF (7.5 mL), H₂O (2.2 mL), Na₂S₂O₅ (411 mg; 2.16 mmol; in 1.5 mL H₂O); Pd/C (56 mg), MeOH (6 mL); Fmoc-OSu (182 mg; 0.54 mmol), NaHCO₃ (123 mg, 1.47 mmol), dioxane/H₂O (1:1; 4 mL), dioxane (2 mL); NaHCO₃ (82 mg; 0.98 mmol), BnBr (175 μ L; 1.47 mmol), dry DMF (6 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 10:1 $\rightarrow$ 5:1.

Yield: 232 mg (46% over 5 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (400 MHz, CDCl₃): 7.76 (d, *J* = 7.2 Hz, 2H, aryl-H), 7.55 (t, *J* = 8.4 Hz, 2H, aryl-H), 7.42 – 7.28 (m, 9H, aryl-H), 7.22 (t, *J* = 8 Hz, 1H, aryl-H), 7.07 (m, 2H, aryl-H), 5.63 (d, *J* = 8 Hz, 1H, NH-Fmoc), 5.19 – 4.98 (m, 3H, COO-CH₂-phenyl + NH-Boc), 4.69 (q, *J* = 8 Hz, 1H, α -CH), 4.33 (m, 2H, CH₂-fluorenyl), 4.15 (t, *J* = 6.8 Hz, 1H, CH-fluorenyl), 3.36 – 3.20 (m, 4H, α -CH-CH₂ + CH₂-NH-Boc), 2.88 (m, 2H, CH₂-CH₂-CH₂-NH-Boc), 1.79 (m, 2H, CH₂-CH₂-NH-Boc), 1.43 + 1.39 (s*, 9H, *t*-Bu). **¹³C NMR** (75 MHz, CDCl₃): 170.9, 156.1, 155.6, 143.8, 143.6, 143.2, 141.3, 134.7, 133.3, 132.5, 128.4, 128.3, 128.0, 127.7, 127.1, 127.0, 126.4, 125.1, 124.2, 120.0, 79.0, 67.3, 67.2, 54.1, 47.0, 40.4, 32.7, 31.7, 29.6, 28.4, 26.9. **¹⁹F NMR** (282 MHz, CDCl₃): - 57.7. **IR** (neat): 3348 (m), 2973 (w), 1744 (m), 1681 (s), 1529 (s), 1451 (m), 1367 (w), 1313 (m), 1253 (s), 1166 (s), 1115 (s), 1092 (m), 1045 (m), 1007 (m), 869 (w), 782 (w), 756 (m), 739 (s), 696 (m), 621 (m), 542 (w). **mp**: 87 – 89 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.45. **[α]_D²⁰** = -1.9° (c = 0.37, DCM). **HRMS**: calcd for C₄₀H₄₁F₃N₂O₆Na [M+Na]⁺ 725.2809; found 725.2830.

Benzyl (2*R*)-3-[2-(3-[[*tert*-butoxy)carbonyl]amino]propyl)-6-phenylphenyl]-2-[[9*H*-fluoren-9-ylmethoxy)carbonyl]amino]propanoate (7e)

Following GP5 using carboximide **5e** (500 mg; 0.92 mmol), KHMDS (0.5 M in toluene; 4.60 mL; 2.30 mmol), tris-azide (427 mg; 1.38 mmol), HOAc (242 μ L; 4.23 mmol), dry THF (3 x 6 mL); isolated azide **6e** (306 mg; 0.52 mmol); H₂O₂ (30%; 212 μ L; 2.08 mmol), LiOH (25 mg; 1.04 mmol), THF (8.0 mL), H₂O (2.3 mL), Na₂S₂O₅ (435 mg; 2.29 mmol; in 1.6 mL H₂O); Pd/C (61 mg), MeOH (6 mL); Fmoc-OSu (192 mg; 0.57 mmol), NaHCO₃ (131 mg, 1.56 mmol), dioxane/H₂O (1:1; 4 mL), dioxane (2 mL); NaHCO₃ (87 mg; 1.04 mmol), BnBr (186 μ L; 1.56 mmol), dry DMF (6 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 10:1 $\rightarrow$ 5:1.

Yield: 183 mg (28% over 5 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (400 MHz, CDCl₃): 7.77 – 7.76 (m, 2H, aryl-H), 7.53 – 7.49 (m, 2H, aryl-H), 7.43 – 7.29 (m, 10H, aryl-H), 7.24 – 7.17 (m, 6H, aryl-H), 7.00 (d, *J* = 6.8 Hz, 1H, aryl-H), 5.03 (m, 2H, COO-CH₂-phenyl), 4.80 (d, *J* = 8.4 Hz, 1H, NH-Fmoc), 4.68 (br s, 1H, NH-Boc), 4.35 – 4.28 (m, 3H, α -CH + CH₂-fluorenyl), 4.12 (t, *J* = 6.8 Hz, 1H, CH-fluorenyl), 3.21 – 3.13 (m, 3H, α -CH-CHH + CH₂-NH-Boc), 3.05 (m, 1H, α -CH-CHH), 2.76 (m, 2H, CH₂-CH₂-CH₂-NH-Boc), 1.82 (m, 2H, CH₂-CH₂-NH-Boc), 1.44 (s, 9H, *t*-Bu). **¹³C NMR** (75 MHz, CDCl₃): 171.6, 156.0, 155.6, 143.9, 143.7, 143.6, 142.0, 141.3, 140.8, 135.1, 131.6, 129.5, 128.9, 128.5, 128.4, 128.3, 128.0, 127.68, 127.66, 127.1, 127.03, 127.00, 126.9, 125.00, 124.98, 119.9, 79.1, 67.0, 66.7, 54.9, 47.1, 40.5, 31.61, 31.57, 30.1, 28.4. **IR** (neat): 3355 (w), 2931 (w), 1709 (s), 1506 (m), 1450 (m), 1391 (w), 1365 (m), 1336 (w), 1247 (m), 1166 (s), 1105 (w), 1046 (m), 758 (s), 739 (s), 703 (m), 621 (w), 539 (w). **mp**: 55 – 57 °C. **R_f** (*n*-hexane/EtOAc,

2:1) = 0.45. $[\alpha]_D^{20} = -2.1^\circ$ ($c = 0.28$, DCM). **HRMS**: calcd for $C_{45}H_{46}N_2O_6Na$ $[M+Na]^+$ 733.3248; found 733.3247.

Benzyl (2R)-3-[2-(3-(((tert-butoxy)carbonyl)amino)propyl)naphthalen-1-yl]-2-(((9H-fluoren-9-ylmethoxy)carbonyl)amino)propanoate (7f)

Following GP5 using carboximide **5f** (450 mg; 0.87 mmol), KHMDS (0.5 M in toluene; 4.36 mL; 2.18 mmol), tris-azide (405 mg; 1.31 mmol), HOAc (229 μ L; 4.00 mmol), dry THF (3 x 6 mL); isolated azide **6f** (235 mg; 0.42 mmol); H_2O_2 (30%; 172 μ L; 1.68 mmol), LiOH (20 mg; 0.84 mmol), THF (6.4 mL), H_2O (1.9 mL), $Na_2S_2O_5$ (352 mg; 1.85 mmol; in 1.3 mL H_2O); Pd/C (47 mg), MeOH (5 mL); Fmoc-OSu (155 mg; 0.46 mmol), $NaHCO_3$ (106 mg, 1.26 mmol), dioxane/ H_2O (1:1; 3.3 mL), dioxane (1.7 mL); $NaHCO_3$ (71 mg; 0.84 mmol), BnBr (150 μ L; 1.26 mmol), dry DMF (5 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 10:1 $\rightarrow$ 5:1.

Yield: 112 mg (19% over 5 steps); colourless solid after recrystallization from DCM/*n*-hexane.

1H NMR (400 MHz, $CDCl_3$): 8.09 (d, $J = 8.8$ Hz, 1H, aryl-H), 7.80 – 7.76 (m, 3H, aryl-H), 7.68 (d, $J = 8.4$ Hz, 1H, aryl-H), 7.63 – 7.50 (m, 3H, aryl-H), 7.43 – 7.39 (m, 3H, aryl-H), 7.35 – 7.29 (m, 3H, aryl-H), 7.24 – 7.19 (m, 3H, aryl-H), 6.83 (d, $J = 6.8$ Hz, 2H, aryl-H), 5.59 (d, $J = 7.6$ Hz, 1H, NH-Fmoc), 4.95 (d, $J = 12$ Hz, 1H, COO-CHH-phenyl), 4.86 (br s, 1H, NH-Boc), 4.72 (q, $J = 7.6$ Hz, 1H, α -CH), 4.64 (d, $J = 12$ Hz, 1H, COO-CHH-phenyl), 4.38 (d, $J = 7.2$ Hz, 2H, CH_2 -fluorenyl), 4.17 (t, $J = 7.2$ Hz, 1H, CH-fluorenyl), 3.66 – 3.52 (m, 2H, α -CH- CH_2), 3.19 (m, 2H, CH_2 -NH-Boc), 2.82 (m, 2H, CH_2 - CH_2 - CH_2 -NH-Boc), 1.79 (m, 2H, CH_2 - CH_2 -NH-Boc), 1.41 (s, 9H, *t*-Bu). **^{13}C NMR** (75 MHz, $CDCl_3$): 172.1, 156.1, 155.6, 143.8, 143.7, 141.3, 138.5, 134.5, 132.8, 132.5, 128.7, 128.3, 128.2, 128.02, 127.97, 127.8, 127.7, 127.0, 126.5, 125.1, 125.0, 123.3, 119.9, 79.1, 67.4, 67.1, 54.7, 47.1, 40.5, 31.83, 31.78, 30.6, 28.4, 26.9. **IR** (neat): 3353 (m), 2972 (w), 1734 (m), 1683 (s), 1519 (s), 1451 (m), 1391 (w), 1366 (m), 1273 (s), 1238 (s), 1168 (s), 1106 (m), 1090 (m), 1032 (m), 999 (m), 871 (w), 816 (w), 782 (w), 756 (m), 738 (s), 695 (m), 621 (m), 541 (w). **mp**: 121 - 124 $^\circ C$. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.35. $[\alpha]_D^{20} = -8.6^\circ$ ($c = 0.30$, DCM). **HRMS**: calcd for $C_{43}H_{44}N_2O_6Na$ $[M+Na]^+$ 707.3092; found 707.3113.

Benzyl (2R)-3-[10-(3-(((tert-butoxy)carbonyl)amino)propyl)phenanthren-9-yl]-2-(((9H-fluoren-9-ylmethoxy)carbonyl)amino)propanoate (7h)

Following GP5 using carboximide **5h** (600 mg; 1.06 mmol), KHMDS (0.5 M in toluene; 5.30 mL; 2.65 mmol), tris-azide (492 mg; 1.59 mmol), HOAc (279 μ L; 4.88 mmol), dry THF (3 x 7 mL); isolated azide **6h** (414 mg; 0.68 mmol); H_2O_2 (30%; 278 μ L; 2.72 mmol), LiOH (33 mg; 1.36 mmol), THF (10.4 mL), H_2O (3.1 mL), $Na_2S_2O_5$ (568 mg; 2.99 mmol; in 2.1 mL H_2O); Pd/C (83 mg), MeOH (8 mL); Fmoc-OSu (253 mg; 0.75 mmol), $NaHCO_3$ (171 mg, 2.04 mmol), dioxane/ H_2O (1:1; 5.3 mL), dioxane (2.7 mL); $NaHCO_3$ (114 mg; 1.36 mmol), BnBr (243 μ L; 2.04 mmol), dry DMF (8 mL).

Eluent for column chromatography: cyclohexane/EtOAc, 10:1 $\rightarrow$ 5:1.

Yield: 174 mg (22% over 5 steps); colourless solid after recrystallization from DCM/*n*-hexane.

¹H NMR (400 MHz, CDCl₃): 8.73 – 8.69 (m, 2H, aryl-H), 8.19 (m, 1H, aryl-H), 8.03 (d, *J* = 6.8 Hz, 1H, aryl-H), 7.77 (d, *J* = 7.2 Hz, 2H, aryl-H), 7.66 – 7.57 (m, 6H, aryl-H), 7.42 – 7.39 (m, 2H, aryl-H), 7.30 (t, *J* = 7.2 Hz, 2H, aryl-H), 7.12 (t, *J* = 7.2 Hz, 1H, aryl-H), 7.00 (t, *J* = 7.6 Hz, 2H, aryl-H), 6.68 (d, *J* = 7.6 Hz, 2H, aryl-H), 5.70 (d, *J* = 5.2 Hz, 1H, NH-Fmoc), 5.02 (br s, 1H, NH-Boc), 4.85 + 4.58 (m, 2H + m, 1H, COO-CH₂-phenyl + α-CH), 4.42 (m, 2H, CH₂-fluorenyl), 4.19 (t, *J* = 6.8 Hz, 1H, CH-fluorenyl), 3.78 – 3.60 (m, 2H, α-CH-CH₂), 3.40 – 3.10 (m, 4H, CH₂-NH-Boc + CH₂-CH₂-CH₂-NH-Boc), 1.86 (m, 2H, CH₂-CH₂-NH-Boc), 1.47 + 1.43 (s*, 9H, *t*-Bu). **¹³C NMR** (75 MHz, CDCl₃): 172.1, 156.1, 155.7, 143.8, 143.7, 141.3, 135.4, 134.2, 131.2, 130.7, 130.4, 129.9, 128.5, 128.2, 128.1, 127.9, 127.7, 127.6, 127.0, 126.8, 126.2, 125.9, 125.1, 124.8, 124.1, 123.1, 123.0, 120.0, 81.4, 79.1, 67.4, 67.2, 58.6, 54.6, 47.1, 40.8, 32.7, 30.8, 28.4, 26.5. **IR** (neat): 3346 (w), 2980 (w), 1733 (m), 1688 (s), 1515 (s), 1447 (m), 1366 (w), 1343 (w), 1275 (s), 1238 (s), 1169 (s), 1085 (m), 1031 (m), 1001 (m), 869 (w), 755 (s), 737 (s), 726 (s), 696 (m), 621 (m), 541 (w). **mp**: 184 – 186 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.35. **[α]_D²⁰** = -3.8° (*c* = 0.42, DCM). **HRMS**: calcd for C₄₇H₄₆N₂O₆Na [M+Na]⁺ 757.3248: found 757.3269.

Benzyl (2*R*)-3-[2-(3-[[*tert*-butoxy]carbonyl]amino)propyl]pyren-1-yl]-2-[[*9H*-fluoren-9-ylmethoxy]carbonyl]amino]propanoate (7i)

Following GP5 using carboximide **5i** (520 mg; 0.88 mmol), KHMDS (0.5 M in toluene; 4.40 mL; 2.20 mmol), tris-azide (408 mg; 1.32 mmol), HOAc (232 μL; 4.05 mmol), dry THF (3 x 6 mL); isolated azide **6i** (373 mg; 0.59 mmol); H₂O₂ (30%; 241 μL; 2.36 mmol), LiOH (28 mg; 1.18 mmol), THF (9.0 mL), H₂O (2.7 mL), Na₂S₂O₅ (494 mg; 2.60 mmol; in 1.8 mL H₂O); Pd/C (75 mg), MeOH (7 mL); Fmoc-OSu (219 mg; 0.65 mmol), NaHCO₃ (149 mg, 1.77 mmol), dioxane/H₂O (1:1; 4.7 mL), dioxane (2.3 mL); NaHCO₃ (99 mg; 1.18 mmol), BnBr (211 μL; 1.77 mmol), dry DMF (7 mL).



Eluent for column chromatography: cyclohexane/EtOAc, 10:1 → 5:1.

Yield: 112 mg (17% over 5 steps); colourless solid after recrystallization from DCM/*n*-hexane.



¹H NMR (400 MHz, CDCl₃): 8.70 (m, 1H, aryl-H), 8.33 (m, 1H, aryl-H), 8.20 – 8.10 (m, 2H, aryl-H), 8.03 (m, 1H, aryl-H), 7.97 – 7.94 (m, 2H, aryl-H), 7.78 – 7.74 (m, 2H, aryl-H), 7.66 – 7.54 (m, 3H, aryl-H), 7.40 – 7.37 (m, 2H, aryl-H), 7.32 – 7.22 (m, 2H, aryl-H), 7.14 – 6.98 (m, 2H, aryl-H), 6.86 (m, 1H, aryl-H), 6.68 (d, *J* = 7.6 Hz, 1H, aryl-H), 6.53 (m, 1H, aryl-H), 5.69 (m, 1H, NH-Fmoc), 4.97 – 4.80 + 4.67 (m, 3H + m, 1H, NH-Boc + COO-CH₂-phenyl + α-CH), 4.42 (m, 2H, CH₂-fluorenyl), 4.18 (m, 1H, CH-fluorenyl), 3.95 – 3.60 (m, 2H, α-CH-CH₂), 3.27 – 3.09 (m, 4H, CH₂-NH-Boc + CH₂-CH₂-CH₂-NH-Boc), 1.89 (m, 2H, CH₂-CH₂-NH-Boc), 1.43 (s, 9H, *t*-Bu). **¹³C NMR** (75 MHz, CDCl₃): 172.0, 156.1, 155.6, 143.82, 143.78, 143.7, 141.3, 138.8, 131.1, 130.45, 130.39, 130.3, 129.9, 128.2, 128.0, 127.95, 127.86, 127.7, 127.3, 127.2, 127.0, 126.8, 126.3, 126.2, 125.9, 125.7, 125.2, 125.1, 124.9, 124.7, 123.7, 123.1, 123.0, 120.0, 79.1, 67.4, 67.1, 55.2, 54.6, 47.1, 40.6, 32.4, 31.0, 28.4, 26.9. **IR** (neat): 3344 (w), 2980 (w), 1690 (s), 1517 (s), 1450 (m), 1366 (w), 1344 (w), 1267 (s), 1169 (s), 1087 (m), 1032 (m), 871 (w), 841 (w), 827 (w), 755 (s), 738 (s), 696 (m), 621 (m), 541 (w). **mp**: 147 – 150 °C. **R_f** (*n*-hexane/EtOAc, 2:1) = 0.35. **[α]_D²⁰** = +4.5° (*c* = 0.31, DCM). **HRMS**: calcd for C₄₉H₄₆N₂O₆Na [M+Na]⁺ 781.3248: found 781.3244.

NMR spectra



1-Iodo-2-phenylbenzene (**1e**)





1-Iodonaphthalene (**1f**)





Anthracen-1-yl trifluoromethanesulfonate (**1g**)





9-Iodophenanthrene (**1h**)





1-Iodopyrene (1i)





3-Iodo-1-[(4-methylbenzene)sulfonyl]-1*H*-indole (**1j**)





Methyl (2E)-3-[2,6-bis(3-bromopropyl)phenyl]prop-2-enoate (**2a**)





Methyl (2E)-3-[2-(3-bromopropyl)-6-methylphenyl]prop-2-enoate (**2b**)





Methyl (2E)-3-[2-(3-bromopropyl)-6-methoxyphenyl]prop-2-enoate (**2c**)





Methyl (2E)-3-[2-(3-bromopropyl)-6-(trifluoromethyl)phenyl]prop-2-enoate (**2d**)





Methyl (2E)-3-[2-(3-bromopropyl)-6-phenylphenyl]prop-2-enoate (**2e**)





Methyl (2E)-3-[2-(3-bromopropyl)naphthalen-1-yl]prop-2-enoate (**2f**)





Methyl (2E)-3-[2-(3-bromopropyl)anthracen-1-yl]prop-2-enoate (**2g**)





Methyl (2E)-3-[10-(3-bromopropyl)phenanthren-9-yl]prop-2-enoate (**2h**)





Methyl (2E)-3-[2-(3-bromopropyl)pyren-1-yl]prop-2-enoate (**2i**)





Methyl (2E)-3-[2-(3-bromopropyl)-1-[(4-methylbenzene)sulfonyl]-1H-indol-3-yl]prop-2-enoate (**2j**)





Methyl (2E)-3-[2,6-bis(3-{bis(*tert*-butoxy)carbonyl}amino)propyl]phenyl]prop-2-enoate (**3a**)





Methyl (2E)-3-[2-(3-*bis*[(*tert*-butoxy)carbonyl]amino)propyl)-6-methylphenyl]prop-2-enoate (**3b**)





Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)-6-methoxyphenyl]prop-2-enoate (**3c**)





Methyl (2E)-3-[2-(3-*bis*[(*tert*-butoxy)carbonyl]amino)propyl)-6-(trifluoromethyl)phenyl]prop-2-enoate (**3d**)





Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)-6-phenylphenyl]prop-2-enoate (**3e**)





Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)naphthalen-1-yl]prop-2-enoate (**3f**)





Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)anthracen-1-yl]prop-2-enoate (**3g**)





Methyl (2E)-3-[10-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl) phenanthren-9-yl]prop-2-enoate (**3h**)





Methyl (2E)-3-[2-(3-{bis[(*tert*-butoxy)carbonyl]amino}propyl)pyren-1-yl] prop-2-enoate (**3i**)





tert-Butyl *N*-[3-(2-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}-3-(3-{[(*tert*-butoxy)carbonyl]amino}propyl)phenyl)propyl]carbamate (**5a**)





tert-Butyl *N*-[3-(2-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}-3-methylphenyl)propyl]carbamate (**5b**)





tert-Butyl *N*-[3-(2-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}-3-methoxyphenyl)propyl]carbamate (**5c**)





tert-Butyl *N*-[3-(2-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}-3-(trifluoromethyl)phenyl)propyl]carbamate (**5d**)





tert-Butyl *N*-[3-(2-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}-3-phenylphenyl)propyl]carbamate (**5e**)





tert-Butyl *N*-[3-(1-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}naphthalen-2-yl)propyl]carbamate (**5f**)





tert-Butyl *N*-[3-(1-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl} anthracen-2-yl)propyl]carbamate (**5g**)





tert-Butyl *N*-[3-(10-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}phenanthren-9-yl)propyl]carbamate (**5h**)





tert-Butyl *N*-[3-(1-{3-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-oxopropyl}pyren-2-yl)propyl]carbamate (**5i**)





Benzyl (2R)-3-[2,6-bis(3-[[*tert*-butoxy)carbonyl]amino)propyl)phenyl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino}propanoate (**7a**)





Benzyl (2R)-3-[2-(3-[[*tert*-butoxy)carbonyl]amino}propyl)-6-methylphenyl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino}propanoate (**7b**)





Benzyl (2R)-3-[2-(3-[[*tert*-butoxy)carbonyl]amino}propyl)-6-methoxyphenyl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino}propanoate (**7c**)





Benzyl (2R)-3-[2-(3-[[*tert*-butoxy)carbonyl]amino}propyl)-6-(trifluoro methyl)phenyl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino]propanoate (**7d**)





Benzyl (2R)-3-[2-(3-[[*tert*-butoxy)carbonyl]amino}propyl)-6-phenylphenyl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino}propanoate (**7e**)





Benzyl (2R)-3-[2-(3-[[*tert*-butoxy)carbonyl]amino}propyl)naphthalen-1-yl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino}propanoate (**7f**)



Benzyl (2R)-3-[10-(3-[[*tert*-butoxy)carbonyl]amino]propyl)phenanthren-9-yl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino]propanoate (**7h**)



Benzyl (2R)-3-[2-(3-[[*tert*-butoxy)carbonyl]amino}propyl)pyren-1-yl]-2-[[*(9H*-fluoren-9-ylmethoxy)carbonyl]amino}propanoate (**7i**)




ee-Determination

Racemisation: ^[6]


Amino acid **7c** (33 mg; 50 μ mol) was dissolved in a piperidine-DMF solution (25%; 0.4 mL) and stirred for 1.5 h at room temperature. Afterwards, H₂O and EtOAc were added and the layers were separated. The aq phase was extracted with EtOAc (2x) and the combined organic phases were washed with H₂O. After drying over MgSO₄ the crude reaction mixture was splitted into two parts and the solvent was evaporated. For racemisation the first half was dissolved in HOAc (0.2 mL) in a sealable tube and salicylaldehyde (1.3 μ L; 12.5 μ mol) was added. The mixture was heated to 100 °C for 1 h. After cooling, MeOH was added and the solvent was evaporated. Having treated the sample this way a second time, it was analyzed by HPLC (*rac*-**8c**). The second half was dissolved in a TFA/DCM mixture (1:1, v/v; 0.2 mL) and stirred for 2 h at room temperature. DCM was added; the sample was concentrated in vacuo and treated this way a second time. Afterwards, the sample was analyzed by HPLC (**8c**).

HPLC trace for *rac*-**8c**:



	Ret.time [min]	Start [min]	End [min]	Height [mV]	Area [mV*min]	% Area
1	6.721	6.09	7.51	428.04	80.1804	49.6448
2	7.755	7.51	8.61	397.328	81.3283	50.3554

HPLC trace for enantiomerically enriched **8c**:



	Ret.time [min]	Start [min]	End [min]	Height [mV]	Area [mV*min]	% Area
1	6.517	6.10	7.31	5.21249	2.62358	4.9290
2	7.767	7.38	8.88	135.909	50.6043	95.0710

HPLC System Agilent 1100 Series
 Column: Chiralpak IA
 Eluent: *n*-hexane/propan-2-ol, 10:1
 Flow: 0.8 mL/min
 Detector freq.: 254 nm

References

- [1] US2006/69286 A1, **2006**.
- [2] Bonnaventure, I.; Charette, A.B. *J. Org. Chem.* **2008**, 73, 6330.
- [3] Goldberg, M.A.; Ordas, E.P.; Carsch, G. *J. Am. Chem. Soc.* **1947**, 69, 260.
- [4] Suzuki, H.; Kondo, A.; Inouye, M.; Ogawa, T. *Synthesis* **1986**, 121.
- [5] Mitsudo, K.; Thansandote, P.; Wilhelm, T.; Mariampillai, B.; Lautens, M. *Org. Lett.* **2006**, 8, 3939.
- [6] Yamada, S.; Hongo, C.; Yoshioka, R.; Chibata, I. *J. Org. Chem.* **1983**, 48, 843.